[go: up one dir, main page]

WO2008076904A1 - Bis-sulfhydryl macrocyclization systems - Google Patents

Bis-sulfhydryl macrocyclization systems Download PDF

Info

Publication number
WO2008076904A1
WO2008076904A1 PCT/US2007/087615 US2007087615W WO2008076904A1 WO 2008076904 A1 WO2008076904 A1 WO 2008076904A1 US 2007087615 W US2007087615 W US 2007087615W WO 2008076904 A1 WO2008076904 A1 WO 2008076904A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
peptidomimetic macrocycle
peptidomimetic
macrocycle
substituted
Prior art date
Application number
PCT/US2007/087615
Other languages
French (fr)
Other versions
WO2008076904A9 (en
Inventor
Huw M. Nash
Original Assignee
Aileron Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aileron Therapeutics, Inc. filed Critical Aileron Therapeutics, Inc.
Priority to AU2007333846A priority Critical patent/AU2007333846B2/en
Priority to CA2686827A priority patent/CA2686827C/en
Priority to CN200780050407.3A priority patent/CN101636407B/en
Priority to JP2009541617A priority patent/JP5656407B2/en
Priority to EP07869296.9A priority patent/EP2094721B1/en
Priority to BRPI0720306-3A priority patent/BRPI0720306A2/en
Priority to HK10104096.3A priority patent/HK1137184B/en
Publication of WO2008076904A1 publication Critical patent/WO2008076904A1/en
Priority to IL199301A priority patent/IL199301A/en
Publication of WO2008076904A9 publication Critical patent/WO2008076904A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Definitions

  • the present invention provides novel peptidomimetic macrocycles and methods for their preparation and use.
  • the synthesis of these peptidomimetic macrocycles involves (1) synthesizing a precursor peptide containing two free -SH moieties; and (2) contacting the precursor peptide with a bis-alkylating reagent to yield a novel peptidomimetic macrocycle.
  • This general method permits the covalent linkage of at least two free thiolate moieties in a precursor peptide to yield novel compounds that exhibit improved biological properties such as structural stability, affinity for a target, resistance to proteolytic degradation and cell penetrance.
  • this general method permits the rapid and selective incorporation of a broad diversity of moieties into the peptidomimetic macrocycle to permit the generation of a library of related macrocycles.
  • This general method also permits the facile incorporation of labels (e g., radioisotopes, chemiluminescent or fluorescent labels) or therapeutic agents.
  • labels e g., radioisotopes, chemiluminescent or fluorescent labels
  • each A, C, D, and E is independently a natural or non-natural ammo acid
  • B is a natural or non-natural amino acid, amino acid [-NH-L 4 -CO-], [-NH-L 4 -SO 2 -], or [-NH-L 4 -],
  • Ri and R 2 are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo—, 3 s y rogen, a y , a eny , a yny , ary a y , eteroa y , cyc oa y , eterocyc oa y , cyc oa y a y , cycloaryl, or heterocycloaryl, unsubstituted or substituted with R 5 ;
  • L] L 2 , L 3 and L 4 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [-R 4 -K-R 4 -In, each being unsubstituted or substituted with R 5 ;
  • R 7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R 5 or part of a cyclic structure with a D residue;
  • Rg is — H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R 5 or part of a cyclic structure with an E residue;
  • v is an integer from 1-1000;
  • w is an integer from 1-1000;
  • x is an integer from 0-10;
  • y is an integer from 0-10;
  • z is an integer from 0-10;
  • n is an integer from 1-5; and
  • x+y+z is at least 3.
  • the peptidomimetic macrocycle comprises an ⁇ -helix and R 8 is -H.
  • at least one of Ri and R 2 is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo—.
  • both Rj and R 2 are independently alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-.
  • At least one OfR 1 and R 2 is alkyl, unsubstituted or substituted with halo—, or both R 1 and R 2 are independently alkyl, unsubstituted or substituted with halo—. In yet other embodiments, at least one OfR 1 and R 2 is methyl, or both R 1 and R 2 are methyl.
  • At least one of D and E is a natural or unnatural amino acid substituted with a high molecular weight lipid or hydrocarbon. In other embodiments, at least one of D and E is attached to an additional macrocycle-forming linker of the formula [-L 1 -S-L 2 -S-L 3 -].
  • a secondary structure of the peptidomimetic macrocycle is more stable than a corresponding secondary structure of a corresponding non-macrocyclic polypeptide.
  • the peptidomimetic macrocycle of the invention also comprises an ⁇ -helix. Such an ⁇ -helix, for example, comprises from 1 turn to 5 turns.
  • Such an ⁇ -helix is, for example, more stable than an ⁇ -helix of a corresponding non-macrocyclic polypeptide.
  • [-L 1 -S-L 2 -S-L 3 -] spans from 1 turn to 5 turns of the ⁇ -helix, such as approximately 1, 2, 3, 4 or 5 turns of the ⁇ -helix.
  • - 1 - - 2 - - 3 - spans approximate y turn o t e ⁇ - e ix xemp ary engt s ot [-L 1 -S-L 2 -S- 3 -] are about 5 A to about 9 A per turn of the ⁇ -helix
  • the length of [-L 1 -S-L 2 -S-L 3 -] is approximately equal to the length of from about 5 carbon-carbon bonds to about 13 carbon-carbon bonds, or from about 7 carbon-carbon bonds to about 10 carbon-carbon bonds.
  • the macrocycle of the invention comprises a ring of about 17 atoms to 25 atoms
  • the peptidomimetic macrocycle of the invention comprises an ⁇ -hehx which comprises about 2 turns.
  • the length of [-Li-S-L 2 -S-L 3 -] is approximately equal to the length of from about 8 carbon-carbon bonds to about 16 carbon-carbon bonds, or from about 10 carbon-carbon bonds to about 13 carbon-carbon bonds.
  • the macrocycle of the invention comprises a ring of about 29 atoms to about 37 atoms.
  • the present invention also provides a compound of Formula Ha-
  • Ri is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl
  • L 1 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [-R 4 -K-R 4 -Jn, unsubstituted or substituted with R 5 ;
  • K is O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ,
  • R 4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene
  • R 5 is independently halogen, alkyl, -OR 6 , -N(Re) 2 , -SR 6 , -SOR 6 , -SO 2 R 6 , -CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent
  • R 6 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent,
  • R 7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, or heterocyclyalkyl;
  • R 9 and R 10 are independently -H or a protecting group suitable for peptide synthesis;
  • n is an integer from 1 to 5;
  • P is -H, -trityl, /7-methoxytrityl, -S f-butyl, or any other protecting group suitable for peptide synthesis; or
  • Ri is alkyl, unsubstituted or substituted with halo—. In other embodiments, Ri is unsubstituted alkyl In yet other embodiments, R 1 is methyl In still other embodiments, at least one of R 9 and Rio is a protected group suitable for peptide synthesis.
  • the present invention also provides a kit comprising a) a compound of Formulas Ha and a compound of Formula lib
  • Ri is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;
  • R 2 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;
  • Li and L 3 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene or [-R 4 -K-R 4 -Jn, each being unsubstituted or substituted with R 5 ;
  • K is O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ;
  • R 4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each R 5 is independently halogen, alkyl, -OR 6 , -N(R 6 J 2 , -SR 6 , -SOR 6 , -SO 2 R 6 , -CO 2 R 6 , -R 6 , a fluorescent moiety, a radioisotope, or a therapeutic agent; each R 6 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent;
  • R 7 and R 8 are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, or heterocyclyalkyl;
  • R 9 and Ri 0 are each independently -H or any protecting group suitable for liquid or solid phase peptide synthesis
  • P is — H, -trityl, p-methoxytrityl, -S f -butyl, or any other protecting group suitable for liquid or solid phase peptide synthesis; or Q and P when taken together form a moiety capable of undergoing chemical transformation into an -SH group; n is an integer from 1 to 5; and b) a macrocycle-forming linker of the structure:
  • L 2 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [-R 11 -K-R 11 -Jn, each being unsubstituted or substituted with R 12 ; each R 11 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each R 12 is independently halogen, alkyl, -OR 13 , -N(R 6 J 13 , -SR 13 , -SOR 13 , -SO 2 R 13 , -CO 2 R 13 , -R 13 , a fluorescent moiety, a radioisotope, or a therapeutic agent; each R 13 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloarylene, heterocycloarylene
  • R 2 is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo.
  • R 1 and R 2 are alkyl.
  • Ri and R 2 are methyl or trifluoromethyl.
  • a method for synthesizing a peptidomimetic macrocycle comprising the step of contacting a peptidomimetic precursor of the Formula III:
  • performing a method of the invention results in the formation of a peptidomimetic macrocycle of Formula (I) as described herein.
  • At least one of Ri and R 2 is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-.
  • both R 1 and R 2 are independently alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-.
  • At least one OfR 1 and R 2 is alkyl, unsubstituted or substituted with halo-, or both Rj and R 2 are independently alkyl, unsubstituted or substituted with halo-.
  • at least one of Ri and R 2 is methyl, or both R 1 and R 2 are methyl.
  • the peptidomimetic precursor is expressed in cells.
  • the peptidomimetic precursor is also purified, in some embodiments, prior to the contacting step.
  • the obtained peptidomimetic macrocycle is, in some instances, purified after the contacting step, and/or refolded after the contacting step.
  • the described method is, for example, performed in solution, or it performed on a solid support.
  • the contacting step is, in some cases, performed in the presence of a target macromolecule that binds to the peptidomimetic precursor under conditions that favor said binding, or it is performed in the presence of a target macromolecule that binds preferentially to the peptidomimetic precursor under conditions that favor said binding.
  • the described method isapplied to synthesize a library of peptidomimetic macrocycles.
  • a peptidomimetic macrocycle prepared by the method of the invention comprises an ⁇ -helix in aqueous solution.
  • the peptidomimetic macrocycle exhibits increased a- helical structure in aqueous solution compared to a corresponding non-macrocyclic polypeptide.
  • the peptidomimetic macrocycle exhibits increased thermal stability, increased biological activity, increased resistance to proteolytic degradation, or increased ability to penetrate living cells compared to a corresponding non-macrocyclic polypeptide.
  • the two thiol moieties of the compound of Formula III are sidechains of an amino acid selected from the group consisting of L-cysteine, D-cysteine, ⁇ - methyl L-cysteine, and ⁇ -methyl D-cysteine.
  • n n- natural amino acids The method described is, for example, performed in a solvent selected from the group consisting of protic solvent, aqueous solvent, organic solvent, and mixtures thereof
  • the solvent is DMF, dichloroethane, NH 3 , NH 3 /MeOH, NH 3 /DMF, or aqueous guamdinium-HCL
  • the solvent is also be a solvent that favors helix formation, such as water
  • L 2 is an alkyl group
  • X and Y are independently chosen halogen groups such as Cl-, Br- or I—
  • FIGURE 1 shows a MALDI spectrum of a peptidomimetic macrocycle of the invention
  • macrocycle refers to a molecule having a chemical structure including a ring or cycle formed by at least 9 covalently bonded atoms
  • peptidomimetic macrocycle refers to a compound comprising a plurality of ammo acid residues joined by a plurality of peptide bonds and at least one macrocycle-forming linker which forms a macrocycle between the a carbon of one naturally-occurring ammo acid residue or non- naturally-occurring amino acid residue or amino acid analog residue and the a carbon of another naturally- occur ⁇ ng amino acid residue or non-naturally-occurring ammo acid residue or amino acid analog residue.
  • the peptidomimetic macrocycles optionally include one or more non-peptide bonds between one or more amino acid residues and/or amino acid analog residues, and optionally include one or more non-naturally- occurring amino acid residues or amino acid analog residues in addition to any which form the macrocycle
  • the term "stability" refers to the maintenance of a defined secondary structure in solution by a peptide or peptidomimetic macrocycle of the invention as measured by circular dichroism, NMR or another biophysical measure, or resistance to proteolytic degradation in vitro or in vivo
  • Non-limitmg examples of secondary structures contemplated in this invention are ⁇ -hehces, /3-turns, and /3-pleated sheets use erein, e erm e i i i y r r i nance o a e ica s ruc ure y a pep i e or peptidomimetic macrocycle of the invention as measured by circular dichroism.
  • the peptidomimetic macrocycles of the invention exhibit at least a 1.25, 1.5, 1.75 or 2-fold increase in ⁇ -helicity as determined by circular dichroism compared to a corresponding non-macrocyclic polypeptide.
  • ⁇ -amino acid or simply “amino acid” refers to a molecule containing both an amino group and a carboxyl group bound to a carbon which is designated the ⁇ -carbon.
  • Suitable amino acids include, without limitation, both the D-and L-isomers of the naturally-occurring amino acids, as well as non-naturally occurring amino acids prepared by organic synthesis or other metabolic routes. Unless the context specifically indicates otherwise, the term amino acid, as used herein, is intended to include amino acid analogs.
  • amino acid analog refers to a molecule which is structurally similar to an amino acid and which can be substituted for an amino acid in the formation of a peptide or peptidomimetic macrocycle.
  • Amino acid analogs include compounds which are structurally identical to an amino acid, as defined herein, except for the inclusion of one or more additional methylene groups between the amino and carboxyl group (e.g., ⁇ -amino / 3-carboxy acids), or for the substitution of the amino or carboxy group by a similarly reactive group (e.g., substitution of the primary amine with a secondary or tertiary amine, or substitution or the carboxy group with an ester).
  • additional methylene groups between the amino and carboxyl group e.g., ⁇ -amino / 3-carboxy acids
  • substitution of the amino or carboxy group by a similarly reactive group e.g., substitution of the primary amine with a secondary or tertiary amine, or substitution or the carboxy group with an ester.
  • a "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of a polypeptide (e.g., a BH3 domain or the p53 MDM2 binding domain) without abolishing or substantially altering its essential biological or biochemical activity (e.g., receptor binding or activation).
  • An "essential” amino acid residue is a residue that, when altered from the wild-type sequence of the polypeptide, results in abolishing or substantially abolishing the polypeptide's essential biological or biochemical activity.
  • a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain.
  • Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., K, R, H), acidic side chains (e.g., D, E), uncharged polar side chains (e.g., G, N, Q, S, T, Y, C), nonpolar side chains (e.g.,
  • a predicted nonessential amino acid residue in a BH3 polypeptide is preferably replaced with another amino acid residue from the same side chain family.
  • member refers to the atoms that form or can form the macrocycle, and excludes substituent or side chain atoms.
  • cyclodecane, 1,2-difluoro-decane and 1,3 -dimethyl cyclodecane are all considered ten-membered macrocycles as the hydrogen or fluoro substituents or methyl side chains do not participate in forming the macrocycle.
  • ⁇ v when used as part of a molecular structure refers to a single bond or a trans or cis double bond.
  • amino acid side chain refers to a moiety attached to the ⁇ -carbon in an amino acid.
  • amino acid side chain for alanine is methyl
  • amino acid side chain for phenylalanine is ,
  • amino acid side chain for tyrosine is 4-hydroxyphenylmethyl, etc.
  • Other non-natural occurring amino acid side chains are also included, for example, those that occur in nature (e.g., an amino acid metabolite) or those that are made synthetically (e.g., an cx,a di-substituted amino acid).
  • polypeptide encompasses two or more naturally or non-naturally-occurring amino acids joined by a covalent bond (e.g., an amide bond). Polypeptides as described herein include full length proteins (e.g., fully processed proteins) as well as shorter amino acids sequences (e.g., fragments of naturally occurring proteins or synthetic polypeptide fragments).
  • halo or “halogen” refers to fluorine, chlorine, bromine or iodine or a radical thereof.
  • alkyl refers to a hydrocarbon chain that is a straight chain or branched chain, containing the indicated number of carbon atoms.
  • Ci-Ci 0 indicates that the group has from 1 to 10 (inclusive) carbon atoms in it.
  • alkyl is a chain (straight or branched) having 1 to 20 (inclusive) carbon atoms in it.
  • alkylene refers to a divalent alkyl (i.e., -R-).
  • alkenyl refers to a hydrocarbon chain that is a straight chain or branched chain having one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C 2 -Ci 0 indicates that the group has from 2 to 10 (inclusive) carbon atoms in it.
  • lower alkenyl refers to a C 2 -Ce alkenyl chain. In the absence of any numerical designation, “alkenyl” is a chain (straight or branched) having 2 to 20 (inclusive) carbon atoms in it.
  • alkynyl refers to a hydrocarbon chain that is a straight chain or branched chain having one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C 2 -Ci 0 indicates that the group has from 2 to 10 (inclusive) carbon atoms in it.
  • lower alkynyl refers to a C 2 -Ce alkynyl chain.
  • alkynyl is a chain (straight or branched) having 2 to 20 (inclusive) carbon atoms in it.
  • aryl refers to a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring are substituted by a substituent. Examples of aryl groups include phenyl, naphthyl and the like.
  • arylalkyl or the term “aralkyl” refers to alkyl substituted with an aryl.
  • arylalkoxy refers to an alkoxy substituted with aryl.
  • Arylalkyl refers to an aryl group, as defined above, wherein one of the aryl group's hydrogen atoms has been replaced with a C 1 -C 5 alkyl group, as defined above.
  • Representative examples of an arylalkyl group include, but are not limited to, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3- ethylphenyl, 4-ethylphenyl, 2- ⁇ ro ⁇ yl ⁇ henyl, 3-propylphenyl, 4-propylphenyl, 2-butylphenyl, 3- butylphenyl, 4-butylphenyl, 2-pentylphenyl, 3-pentylphenyl, 4-pentylphenyl, 2-iso ⁇ ropylphenyl, 3- isopropylphenyl, 4-isopropylphenyl, 2-isobutylphenyl, 3-isobutylphenyl,
  • Arylamido refers to an aryl group, as defined above, wherein one of the aryl group's hydrogen atoms has been replaced with one or more -C(O)NH 2 groups.
  • Representative examples of an arylamido group include 2-C(O)NH2-phenyl, 3-C(O)NH 2 -phenyl, 4-C(O)NH 2 -phenyl, 2-C(O)NH 2 -pyridyl, 3-C(O)NH 2 -pyridyl, and 4-C(O)NH 2 -pyridyl
  • Alkylheterocycle refers to a Ci-C 5 alkyl group, as defined above, wherein one of the Ci-C 5 alkyl group's hydrogen atoms has been replaced with a heterocycle.
  • alkylheterocycle , - - , - 2 2 - , - ⁇ 2 2 , 2 - morpholine, and -CH 2 CH 2 CH 2 -ImIdEZoIe.
  • Alkylamido refers to a C]-C 5 alkyl group, as defined above, wherein one of the C r C 5 alkyl group's hydrogen atoms has been replaced with a -C(O)NH 2 group.
  • Representative examples of an alkylamido group include, but are not limited to, -CH 2 -C(O)NH 2 , -CH 2 CH 2 -C(O)NH 2 , -CH 2 CH 2 CH 2 C(O)NH 2 , -
  • Alkanol refers to a Cj-C 5 alkyl group, as defined above, wherein one of the Ci-C 5 alkyl group's hydrogen atoms has been replaced with a hydroxyl group.
  • alkanol group include, but are not limited to, -CH 2 OH, -CH 2 CH 2 OH, -CH 2 CH 2 CH 2 OH, -CH 2 CH 2 CH 2 CH 2 OH, -CH 2 CH 2 CH 2 CH 2 OH, -CH 2 CH 2 CH 2
  • Alkylcarboxy refers to a Ci-C 5 alkyl group, as defined above, wherein one of the Ci-C 5 alkyl group's hydrogen atoms has been replaced with a — COOH group.
  • Representative examples of an alkylcarboxy group include, but are not limited to, -CH 2 COOH, -CH 2 CH 2 COOH, -CH 2 CH 2 CH 2 COOH, - CH 2 CH 2 CH 2 CH 2 COOH, -CH 2 CH(COOH)CH 3 , -CH 2 CH 2 CH 2 CH 2 CH 2 COOH, -CH 2 CH(COOH)CH 2 CH 3 , -
  • cycloalkyl as employed herein includes saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, preferably 3 to 8 carbons, and more preferably 3 to 6 carbons, wherein the cycloalkyl group additionally is optionally substituted.
  • Some cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.
  • heteroaryl refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein O, 1, 2, 3, or 4 atoms of each ring aresubstituted by a substituent.
  • heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like.
  • heteroarylalkyl or the term “heteroaralkyl” refers to an alkyl substituted with a heteroaryl.
  • heteroarylalkoxy refers to an alkoxy substituted with heteroaryl.
  • heteroaryl refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein O, 1, 2, 3, or 4 atoms of each ring aresubstituted by a substituent.
  • heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like.
  • heteroarylalkyl or the term “heteroaralkyl” refers to an alkyl substituted with a heteroaryl.
  • heteroarylalkoxy refers to an alkoxy substituted with heteroaryl.
  • heterocyclyl refers to a nonaromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms ifbicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 a oms o ea i ri u i u y a su s i uen xamp es o e erocyc y groups mc u e piperazmy , pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like [0055
  • the compounds of this invention contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures All such isomeric forms of these compounds are included in the present invention unless expressly provided otherwise
  • the compounds of this invention are also represented in multiple tautome ⁇ c forms, in such instances, the invention includes all tautomeric forms of the compounds described herein (e.g , if alkylation of a ring system results m alkylation at multiple sites, the invention includes all such reaction products) All such isomenc forms of such compounds are included in the present invention unless expressly provided otherwise All crystal forms of the compounds described herein are included m the present invention unless expressly provided otherwise
  • variable ( ⁇ e , p ⁇ 0 1) increase or decrease of at least 5%
  • the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values withm that range
  • the variable is equal to any integer value within the numerical range, including the end-points of the range
  • the variable is equal to any real value withm the numerical range, including the end-points of the range
  • a variable which is described as having values between 0 and 2 takes the values 0, 1 or 2 if the variable is inherently discrete, and takes the values 0 0, 0 1, 0 01, 0 001, or any other real values >0 and ⁇ 2 if the variable is inherently continuous
  • the present invention provides peptidomimetic macrocycles of Formula (I)
  • each A, C, D, and E is independently a natural or non-natural amino acid
  • B is a natural or non-natural amino acid, amino acid [-NH-L 4 -CO-], [-NH-L 4 -SO 2 -], or [-NH-L 4 -];
  • Ri and R 2 are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;
  • R 3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R 5 ;
  • L 1 , L 2 , L 3 and L 4 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [-R 4 -K-R 4 -Jn, each being unsubstituted or substituted with R 5 ;
  • K is O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ;
  • each R 4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;
  • each R 5 is independently halogen, alkyl, -OR 6 , -N(Rg) 2 , -SR 6 , -SOR 6 , -SO 2 R 6 , -CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent;
  • each R 6 is independently
  • R 7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R 5> or part of a cyclic structure with a D residue;
  • R 8 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R 5> or part of a cyclic structure with an E residue;
  • v is an integer from 1-1000;
  • w is an integer from 1-1000;
  • x is an integer from 0-10;
  • y is an integer from 0-10;
  • z is an integer from
  • x+y+z is at least 3. In other embodiments of the invention, x+y+z is 3, 4, 5, 6, 7, 8, 9 or 10.
  • Each occurrence of A, B, C, D or E in a macrocycle or macrocycle precursor of the invention is independently selected.
  • a sequence represented by the formula [A] x when x is 3, encompasses embodiments where the amino acids are not identical, e.g. Gin— Asp— Ala as well as embodiments where the amino acids are identical, e.g. Gln-Gln-Gln. This applies for any value of x, y, or z in the indicated ranges.
  • the peptidomimetic macrocycle of the invention comprises a secondary structure which is an ⁇ -helix and Rg is -H, allowing intrahelical hydrogen bonding.
  • the length of the macrocycle-forming linker [-L 1 -S-L 2 -S L 3 -] as measured from a first Ca to a second Ca is selected to stabilize a desired secondary peptide structure, such as an ⁇ -helix formed by residues of the peptidomimetic macrocycle including, but not necessarily limited to, those between the first Ca to a second Co. , - . ,
  • A, B and/or C in the compound of Formula I include one or more ⁇ -helices.
  • ⁇ -helices include between 3 and 4 amino acid residues per turn.
  • the ⁇ -helix of the peptidomimetic macrocycle includes 1 to 5 turns and, therefore, 3 to 20 amino acid residues.
  • the ⁇ -helix includes 1 turn, 2 turns, 3 turns, 4 turns, or 5 turns.
  • the macrocycle-forming linker stabilizes an ⁇ -helix motif included within the peptidomimetic macrocycle.
  • the length of the macrocycle-forming linker [-L 1 -S-L 2 -S-L 3 -] from a first Ca to a second Ca is selected to increase the stability of an ⁇ -helix.
  • the macrocycle- forming linker spans from 1 turn to 5 turns of the ⁇ -helix.
  • the macrocycle-forming linker spans approximately 1 turn, 2 turns, 3 turns, 4 turns, or 5 turns of the ⁇ -helix.
  • the length of the macrocycle-forming linker is approximately 5 A to 9 A per turn of the ⁇ -helix, or approximately 6 A to 8 A per turn of the ⁇ -helix.
  • the length is equal to approximately 5 carbon-carbon bonds to 13 carbon-carbon bonds, approximately 7 carbon-carbon bonds to 11 carbon-carbon bonds, or approximately 9 carbon-carbon bonds.
  • the length is equal to approximately 8 carbon-carbon bonds to 16 carbon-carbon bonds, approximately 10 carbon-carbon bonds to 14 carbon-carbon bonds, or approximately 12 carbon-carbon bonds.
  • the macrocycle-forming linker spans approximately 3 turns of an ⁇ -helix, the length is equal to approximately 14 carbon-carbon bonds to 22 carbon-carbon bonds, approximately 16 carbon-carbon bonds to 20 carbon- carbon bonds, or approximately 18 carbon-carbon bonds.
  • the length is equal to approximately 20 carbon-carbon bonds to 28 carbon-carbon bonds, approximately 22 carbon-carbon bonds to 26 carbon-carbon bonds, or approximately 24 carbon-carbon bonds.
  • the macrocycle-forming linker spans approximately 5 turns of an ⁇ -helix, the length is equal to approximately 26 carbon-carbon bonds to 34 carbon-carbon bonds, approximately 28 carbon-carbon bonds to 32 carbon-carbon bonds, or approximately 30 carbon-carbon bonds.
  • the linkage contains approximately 4 atoms to 12 atoms, approximately 6 atoms to 10 atoms, or approximately 8 atoms.
  • the linkage contains approximately 7 atoms to 15 atoms, approximately 9 atoms to 13 atoms, or approximately 11 atoms.
  • the linkage contains approximately 13 atoms to 21 atoms, approximately 15 atoms to 19 atoms, or approximately 17 atoms.
  • the linkage contains approximately 19 atoms to 27 atoms, approximately 21 atoms to 25 atoms, or approximately 23 atoms.
  • the linkage contains approximately 25 atoms to 33 atoms, approximately 27 atoms to 31 atoms, or approximately 29 atoms.
  • the resulting macrocycle forms a ring containing approximately 17 members to 25 members, approximately 19 members to 23 members, or approximately 21 members.
  • the macrocycle-forming linker spans approximately 2 turns of the ⁇ -helix, the resulting macrocycle forms a ring containing approximately 29 members to 37 members, approximately 31 members to 35 members, or approximately 33 members.
  • the resulting macrocycle forms a ring containing approximately 44 members to 52 members, approximately 46 members to 50 members, or approximately 48 members.
  • the macrocyc e-i rmmg in er spans approxima e y urns o e ⁇ - e ix
  • e resulting macrocycle forms a ring containing approximately 59 members to 67 members, approximately 61 members to 65 members, or approximately 63 members.
  • the macrocycle-forming linker spans approximately 5 turns of the a- helix, the resulting macrocycle forms a ring containing approximately 74 members to 82 members, approximately 76 members to 80 members, or approximately 78 members.
  • D and/or E are further modified in order to facilitate cellular uptake.
  • lipidating or PEGylating a peptide facilitates in some embodiments cellular uptake, increase bioavailability, increase blood circulation, alter pharmacokinetics, decrease immunogenic ity and/or decrease the needed frequency of administration.
  • the synthesis of the peptidomimetic macrocycles of the invention involves a multi-step process that features the (1) synthesis of a precursor peptide or peptidomimetic containing two free -SH moieties; and (2) then contacting the precursor with a bis-alkylating reagent to generate two new covalent bonds.
  • Macrocycles or macrocycle precursors are synthesized, for example, by solution phase or solid-phase methods, and can contain both naturally-occurring and non-naturally-occurring amino acids. See, for example, Hunt, "The Non-Protein Amino Acids” in Chemistry and Biochemistry of the Amino Acids, edited by G.C. Barrett, Chapman and Hall, 1985.
  • the thiol moieties are the side chains of the amino acid residues L-cysteine, D-cysteine, ⁇ -methyl-L cysteine, ⁇ -methyl-D-cysteine, L- homocysteine, D-homocysteine, ⁇ -methyl-L-homocysteine or ⁇ -methyl-D -homocysteine.
  • the bis- alkylating reagent is of the general formula X-L 2 -Y wherein L 2 is a linker moiety and X and Y are leaving groups that are displaced by -SH moieties to form bonds with L 2 .
  • X and Y are halogens such as I, Br, or Cl.
  • the peptidomimetic macrocycle exhibits improved biological properties such as increased structural stability, increased affinity for a target, increased resistance to proteolytic degradation and/or increased cell penetrance when compared to the precursor peptide or peptidomimetic.
  • the peptidomimetic macrocycle comprises one or more ⁇ -helices in aqueous solutions and/or exhibits an increased degree of ⁇ -helicity when compared to the precursor peptide or peptidomimetic.
  • the method provides a route towards the synthesis of a library of peptidomimetic macrocycles by varying the X-L 2 -Y reagent, and in some embodiments the linker element L 2 is optimized to improve the biological or pharmacological properties of the resultant peptidomimetic macrocycle.
  • the macrocycle-forming linker increases cell permeability of the peptidomimetic macrocycle.
  • the macrocycle-forming linker increases the overall hydrophobicity of the peptidomimetic macrocycle relative to the precursor peptide or peptidomimetic.
  • Any protein or polypeptide with a known primary amino acid sequence which contains a secondary structure believed to impart biological activity is the subject of the present invention.
  • the sequence of the polypeptide can be analyzed and the sulfhydryl containing amino acid analogs of the invention can be substituted at the appropriate positions.
  • the appropriate positions are determined by ascertaining which molecular surface(s) of the secondary structure is (are) required for biological activity and, therefore, across which other surface(s) the macrocycle forming linkers of the invention can form a macrocycle without sterically blocking the surface(s) required for biological activity.
  • Such determinations are made using methods such as X-ray crystallography of complexes between the secondary structure and a natural binding partner to visualize residues (and surfaces) critical for activity; by sequential mutagenesis of residues in the secondary structure to functionally identify residues (and surfaces) critical for activity; or y o er me o s y suc e ermina ions, e appropria e amino aci s are suostirute ⁇ witn trie amino aci s analogs and macrocycle-forming linkers of the invention
  • one surface of the helix e g , a.
  • the peptide sequence is derived from the BCL-2 family of proteins
  • the BCL-2 family is defined by the presence of up to four conserved BCL-2 homology (BH) domains designated BHl, BH2, BH3, and BH4, all of which include ⁇ -hehcal segments (Chittenden et ⁇ l (1995),
  • Anti-apoptotic proteins such as BCL-2 and BCL-X L , display sequence conservation in all BH domains.
  • Pro-apoptotic proteins are divided into "multidomam” family members (e g , BAK, BAX), which possess homology in the BHl, BH2, and BH3 domains, and "BH3-domarn only" family members (e g , BID, BAD, BIM, BIK, NOXA, PUMA), that contain sequence homology exclusively in the BH3 amphipathic ⁇ -hehcal segment BCL-2 family members have the capacity to form homo- and heterodimers, suggesting that competitive binding and the ratio between pro- and anti-apoptotic protein levels dictates susceptibility to death stimuli.
  • multidomam e g , BAK, BAX
  • BH3-domarn only family members e g , BID, BAD, BIM, BIK, NOXA, PUMA
  • Anti-apoptotic proteins function to protect cells from pro-apoptotic excess, i e , excessive programmed cell death Additional “security” measures include regulating transcription of pro-apoptotic proteins and maintaining them as inactive conformers, requiring either proteolytic activation, dephosphorylation, or hgand-mduced conformational change to activate pro-death functions.
  • death signals received at the plasma membrane trigger apoptosis via a mitochondrial pathway
  • the mitochondria can serve as a gatekeeper of cell death by sequestering cytochrome c, a critical component of a cytosolic complex which activates caspase 9, leading to fatal downstream proteolytic events
  • Multidomam proteins such as BCL- 2/BCL-X L and BAK/BAX play dueling roles of guardian and executioner at the mitochondrial membrane, with their activities further regulated by upstream BH3-only members of the BCL-2 family.
  • BID is a member of the BH3-domam only family of pro-apoptotic proteins, and transmits death signals received at the plasma membrane to effector pro-apoptotic proteins at the mitochondrial membrane
  • BID has the capability of interacting with both pro- and anti-apoptotic proteins, and upon activation by caspase 8, triggers cytochrome c release and mitochondrial apoptosis
  • Deletion and mutagenesis studies determined that the amphipathic ⁇ -hehcal BH3 segment of pro-apoptotic family members functions as a death domain and thus represents a c ⁇ tical structural motif for interacting with multidomam apoptotic proteins
  • Structural studies have demonstrated that the BH3 helix interacts with anti-apoptotic proteins by inserting into a hydrophobic groove formed by the interface of BH 1 , 2 and 3 domains
  • Activated BID can be bound and sequestered by anti-apoptotic proteins (e g , BCL-2 and BCL
  • BAD displays preferential binding to anti-apoptotic family members, BCL-2 and BCL-X L
  • BAD BH3 domain exhibits high affinity binding to BCL-2
  • BAD BH3 peptide is unable to activate cytochrome c release from mitochondria in vitro, suggesting that
  • BAD is not a direct activator of BAX/BAK Mitochondria that over-express BCL-2 are resistant to BID- induced cytochrome c release, but co-treatment with BAD can restore BID sensitivity.
  • BID-like proteins that directly activate mitochondrial apoptosis
  • BAD-like proteins that have the capacity to sensitize mitochondria to BID-like pro-apoptotics by occupying the binding pockets of multidomain anti-apoptotic proteins.
  • BCL-2 family member proteins amendable to the methodology disclosed herein have been disclosed (Walensky et al. (2004), Science 305:1466; and Walensky et al., U.S. Patent Publication No. 2005/0250680, the entire disclosures of which are incorporated herein by reference).
  • the peptide sequence is derived from the tumor suppressor p53 protein which binds to the oncogene protein MDM2.
  • the MDM2 binding site is localized within a region of the p53 tumor suppressor that forms an a helix.
  • Lane et al. disclose that the region of ⁇ 53 responsible for binding to MDM2 is represented approximately by amino acids 13-31 (PLSQETFSDLWKLLPENNV) of mature human P53 protein.
  • Other modified sequences disclosed by Lane are also contemplated in the instant invention.
  • the interaction of p53 and MDM2 has been discussed by Shair et al.
  • novel ⁇ -helix structures generated by the method of the present invention are engineered to generate structures that bind tightly to the helix acceptor and disrupt native protein-protein interactions. These structures are then screened using high throughput techniques to identify optimal small molecule peptides.
  • the novel structures that disrupt the MDM2 interaction are useful for many applications, including, but not limited to, control of soft tissue sarcomas (which over-expresses MDM2 in the presence of wild type p53).
  • small molecules disrupters of MDM2-p53 interactions are used as adjuvant therapy to help control and modulate the extent of the ⁇ 53 dependent apoptosis response in conventional chemotherapy.
  • Peptide sequences listed in Table 1 are human sequences which target the BH3 binding site and are implicated in cancers, autoimmune disorders, metabolic diseases and other human disease conditions.
  • 'Peptide sequences listed in Table 2 are human sequences which target the BH3 binding site and are implicated in cancers, autoimmune disorders, metabolic diseases and other human disease conditions.
  • 'Peptide sequences listed in Table 3 are human sequences which target the p53 binding site of mdm2/x and are implicated in cancers.
  • peptidomimetic macrocycles of the invention are made, for example, by chemical synthesis methods, such as described in Fields et al., Chapter 3 in Synthetic Peptides: A User's Guide, ed. Grant, W. H. Freeman & Co., New York, N. Y., 1992, p. 77.
  • peptides are synthesized using the automated Merrifield techniques of solid phase synthesis with the amine protected by either tBoc or Fmoc chemistry using side chain protected amino acids on, for example, an automated peptide synthesizer (e.g., Applied Biosystems (Foster City, CA), Model 430A, 431, or 433).
  • One manner of producing the precursor peptides and peptidomimetics described herein uses solid phase peptide synthesis (SPPS).
  • SPPS solid phase peptide synthesis
  • the C-terminal amino acid is attached to a cross-linked polystyrene resin via an acid labile bond with a linker molecule.
  • This resin is insoluble in the solvents used for synthesis, making it relatively simple and fast to wash away excess reagents and by-products.
  • the N-terminus is protected with the Fmoc group, which is stable in acid, but removable by base. Side chain functional groups are protected as necessary with base stable, acid labile groups.
  • Longer precursor peptides are produced, for example, by conjoining individual synthetic peptides using native chemical ligation.
  • the longer synthetic peptides are biosynthesized by well known recombinant DNA and protein expression techniques. Such techniques are provided in well-known standard manuals with detailed protocols.
  • a gene encoding a precursor peptide of this invention the amino acid sequence is reverse translated to obtain a nucleic acid sequence encoding the amino acid sequence, preferably with codons that are optimum for the organism in which the gene is to be expressed.
  • a synthetic gene is made, typically by synthesizing oligonucleotides which encode the peptide and any regulatory elements, if necessary.
  • the synthetic gene is inserted in a suitable cloning vector and transfected into a host cell.
  • the peptide is then expressed under suitable conditions appropriate for the selected expression system and host.
  • the peptide is purified and characterized by standard methods.
  • the precursor peptides and peptidomimetics are made, for example, in a high-throughput, combinatorial fashion using, for example, a high-throughput polychannel combinatorial synthesizer ⁇ e.g., Model Apex 396 multichannel peptide synthesizer from AAPPTEC, Inc., Louisville, KY).
  • a high-throughput polychannel combinatorial synthesizer ⁇ e.g., Model Apex 396 multichannel peptide synthesizer from AAPPTEC, Inc., Louisville, KY).
  • ie iscussion e ow is o ere i us ra e cer ain o e iver me v u e in assem ing the compounds of the invention.
  • the discussion is not intended to limit the scope of reactions or reaction sequences that are useful in preparing the compounds of the present invention.
  • the peptidomimetic precursor contains two -SH moieties and is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N- ⁇ -Fmoc amino acids such as N- ⁇ - Fmoc-S-trityl-L-cysteine or N- ⁇ -Fmoc-S-trityl-D-cysteine.
  • SPPS solid-phase peptide synthesis
  • Alpha-methylated versions of D-cysteine or L- cysteine are generated by known methods (Seebach et al. (1996), Angew. Chem. Int. Ed. Engl.
  • N- ⁇ -Fmoc-S-trityl monomers 35:2708- 2748, and references therein.
  • the precursor peptidomimetic is then deprotected and cleaved from the solid-phase resin by standard conditions ⁇ e.g. , strong acid such as 95% TFA).
  • the precursor peptidomimetic is reacted as a crude mixture or is purified prior to reaction with X-L 2 -Y in organic or aqueous solutions.
  • the alkylation reaction is performed under dilute conditions (i.e.
  • the alkylation is performed in an aqueous solution such as 6M guanidinium HCL, pH 8 (Brunei et al. (2005), Chem. Commun. (20):2552-2554).
  • the solvent used for the alkylation reaction is DMF or dichloro ethane.
  • the precursor peptidomimetic contains two or more -SH moieties, of which two are specially protected to allow their selective deprotection and subsequent alkylation for macrocycle formation.
  • the precursor peptidomimetic is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N- ⁇ -Fmoc amino acids such as N- ⁇ -Fmoc-S-p-methoxytrityl-L-cysteine or N- ⁇ - Fmoc-S-p-methoxytrityl-D-cysteine.
  • SPPS solid-phase peptide synthesis
  • N- ⁇ -Fmoc amino acids such as N- ⁇ -Fmoc-S-p-methoxytrityl-L-cysteine or N- ⁇ - Fmoc-S-p-methoxytrityl-D-cysteine.
  • Alpha-methylated versions of D-cysteine or L-cysteine are generated y nown me o
  • the reaction takes place in the presence of a hindered base such as diisopropylethylamine.
  • a hindered base such as diisopropylethylamine.
  • the alkylation reaction is performed in organic solutions such as liquid NH 3 (Mosberg et al. (1985), J. Am.Chem. Soc. 107:2986-2987; Szewczuk et al. (1992), Int. J. Peptide Protein Res. 40 :233-242), NH 3 /MeOH or NH 3 /DMF (Or et al. (1991), J. Org. Chem. 56:3146- 3149).
  • the alkylation reaction is performed in DMF or dichloroethane.
  • the peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions ⁇ e.g., strong acid such as 95% TFA).
  • the peptidomimetic precursor contains two or more -SH moieties, of which two are specially protected to allow their selective deprotection and subsequent alkylation for macrocycle formation.
  • the precursor peptidomimetic is then reacted on the resin with a molar excess OfX-L 2 -Y in an organic solution.
  • the reaction takes place in the presence of a hindered base such as diisopropylethylamine.
  • the Mmt protecting group of the peptidomimetic precursor is then selectively cleaved by standard conditions (e.g., mild acid such as 1% TFA in DCM).
  • the peptidomimetic precursor is then cyclized on the resin by treatment with a hindered base in organic solutions.
  • the alkylation reaction is performed in organic solutions such as NH 3 /MeOH or NH 3 /DMF (Or et at. (1991), J. Org. Chem. 56:3146-3149).
  • the peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA).
  • the peptidomimetic precursor contains two L-cysteine moieties.
  • the peptidomimetic precursor is synthesized by known biological expression systems in living cells or by known in vitro, cell-free, expression methods.
  • the precursor peptidomimetic is reacted as a crude mixture or is purified prior to reaction with X-L2-Y in organic or aqueous solutions.
  • the alkylation reaction is performed under dilute conditions (i.e. 0.15 mmol/L) to favor macrocyclization and to avoid polymerization.
  • the alkylation reaction is performed in organic solutions such as liquid NH 3 (Mosberg et al. (1985), J. Am.Chem. Soc.
  • the alkylation is performed in an aqueous solution such as 6M guanidinium HCL, pH 8 (Brunei et al. (2005), Chem. Commun. (20):2552-2554). In other embodiments, the alkylation is performed in DMF or dichloroethane.
  • the alkylation is performed in non- denaturing aqueous solutions, and in yet another embodiment the alkylation is performed under conditions that favor ⁇ -helical structure formation. In yet another embodiment, the alkylation is performed under conditions that favor the binding of the precursor peptidomimetic to another protein, so as to induce the formation of the bound or-helical conformation during the alkylation.
  • X and Y are envisioned which are suitable for reacting with thiol groups.
  • each X or Y is independently be selected from the general category shown in Table 5.
  • X and Y are halides such as -Cl, -Br or -I.
  • Table 6 shows exemplary macrocycles of the invention.
  • a corresponding non-macrocyclic polypeptide is the BID BH3 polypeptide sequence fragment DIIRNIARHLAQVGDSMDRSI.
  • N L represents norleucine and replaces a methionine residue. It is envisioned that similar linkers are used to synthesize peptidomimetic macrocycles based on the polypeptide sequences disclosed in Table 1 through Table 4.
  • the present invention contemplates the use of both naturally-occurring and non-naturally-occurring amino acids and amino acid analogs in the synthesis of the peptidomimetic macrocycles described above.
  • Any amino acid or amino acid analog amenable to the synthetic methods employed for the synthesis of stable bis-sulfhydryl containing peptidomimetic macrocycles can be used in the present invention
  • cysteine is contemplated as a useful amino acid in the present invention
  • sulfur containing amino acids other than cysteine that contain a different amino acid side cham are also useful in the invention
  • cysteine contains one methylene unit between the ⁇ -carbon of the amino acid and the terminal — _ o e amino aci si e c ain.
  • Non-limiting examples include L- homocysteine, D-homocysteine, ⁇ -methyl-L-homocysteine and ⁇ -methyl-D-homocysteine.
  • the amino acids and amino acid analogs are of the D- configuration. In other embodiments they are of the L- configuration. In some embodiments, some of the amino acids and amino acid analogs contained in the peptidomimetic are of the D- configuration while some of the amino acids and amino acid analogs are of the L- configuration.
  • amino acid analogs are ⁇ , ⁇ -disubstituted, such as ⁇ -methyl-L-cysteine and ⁇ -methyl-D-cysteine.
  • amino acid analogs are N- alkylated, e.g. , N-methyl-L-cysteine and N-methyl-D-cysteine.
  • Other amino acid analogs useful in the present invention for forming peptidomimetic macrocycles are compounds of Formula Ha:
  • Ri is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl;
  • Li is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [-R 4 -K-R 4 -Jn, unsubstituted or substituted with R 5 ;
  • K is O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ;
  • R 4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene;
  • R 5 is independently halogen, alkyl, -OR 6 , -N(Rg) 2 , -SR 6 , -SOR 6 , -SO 2 R 6 , -CO 2 R 6 , a fluorescent moiety, a radioisotope or a therapeutic agent;
  • R 6 is independently — H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
  • R 7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, or heterocyclyalkyl;
  • Rg and Rio are independently — H or a protecting group suitable for peptide synthesis;
  • n is an integer from 1 to 5;
  • P is — H, -trityl, /7-methoxytrityl, -S ⁇ -butyl, or any other protecting group suitable for peptide synthesis; or
  • either the -NH or the -SH moieties of the amino acid are protected.
  • both moieties are protected, for example protecting groups for either the -NH and the -SH moieties in amino acids.
  • Non-limiting examples of such -NH protecting groups are -Fmoc and -Boc.
  • Non- limiting examples of -SH protecting groups are -trityl, /?-methoxytrityl, and -S 2-butyl.
  • the amino acid is not protected prior to synthesis of the peptidomimetic macrocycle. a e . xemp ary am no ac s o t e nvent on.
  • the present invention includes macrocycle-forming linkers used to link two or more -SH moieties in the peptidomimetic precursors to form the peptidomimetic macrocycles of the invention.
  • the macrocycle-forming linkers impart conformational rigidity, increased metabolic stability and/or increased cell penetrability.
  • the macrocycle-forming linkages stabilize the ⁇ -helical secondary structure of the peptidomimetic macrocyles.
  • the macrocycle-forming linkers are of the formula X-L 2 -Y, wherein both X and Y are the same or different moieties, as defined above.
  • Both X and Y have the chemical characteristics that allow one macrocycle-forming linker -L 2 - to bis alkylate the bis-sulfhydryl containing peptidomimetic precursor.
  • the linker -L 2 - includes alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene, or -R 4 -K-R 4 -, all of which can be optionally substituted with an R 5 group, as defined above.
  • one to three carbon atoms withm the macrocycle-forming linkers -L 2 -, other than the carbons attached to the -SH of the sulfhydryl containing amino acid, are optionally substituted with a heteroatom such as N, S or O.
  • the L 2 component of the macrocycle-forming linker X-L 2 -Y may be varied m length depending on, among other things, the distance between the positions of the two amino acid analogs used to form the peptidomimetic macrocycle. Furthermore, as the lengths of L] and/or L 3 components of the macrocycle- forming linker are varied, the length of L 2 can also be varied in order to create a linker of appropriate overall length for forming a stable peptidomimetic macrocycle.
  • L 2 is an alkylene group of the formula — (CH 2 ), ! - > where n is an integer between about 1 and about 15. For example, n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In other embodiments, L 2 is an alkenylene group. In still other embodiments, L 2 is an aryl group. [0094] Table X shows additional embodiments of X-L 2 -Y groups.
  • Each X and Y in this Table are, for example, independently Cl-, Br- or I—.
  • kits comprising amino acid analogs and/or macrocycle- forming linkers as described herein.
  • the kit contains a) a compound of Formulas Ha and a compound of Formula lib:
  • Ri is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;
  • R 2 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;
  • Li and L 3 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene or [-R 4 -K-R 4 -Jn, each being unsubstituted or substituted with R 5 ;
  • K is O, S, SO, SO 2 , CO, CO 2 , or CONR 3 ;
  • R 4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each R 5 is independently halogen, alkyl, -OR 6 , -N(Rg) 2 , -SR 6 , -SOR 6 , -SO 2 R 6 , -CO 2 R 6 , -R 6 , a fluorescent moiety, a radioisotope, or a therapeutic agent; each R 6 is independently — H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent;
  • R 7 and R 8 are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, or heterocyclyalkyl;
  • R 9 and Ri 0 are each independently -H or any protecting group suitable for liquid or solid phase peptide synthesis
  • P is -H, -trityl, p-methoxytrityl, -S t-butyl, or any other protecting group suitable for liquid or solid phase peptide synthesis; or Q and P when taken together form a moiety capable of undergoing chemical transformation into an -SH group; n is an integer from 1 to 5; and b) a macrocycle-forming linker of the structure:
  • L 2 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [-Rn-K-Rn-]n, each being unsubstituted or substituted with R 12 ; each R 11 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each Ri 2 is independently halogen, alkyl, -OR n , -N(Re) n , -SR n , -SOR n , -SO 2 R 13 , -CO 2 R 13 , -R n , a fluorescent moiety, a radioisotope, or a therapeutic agent; 13 - , , , , , , , heterocyclyalkyl, a fluorescent moiety, a radioisotope, or
  • X and Y are each independently a reactive group capable of reacting with a thiol group.
  • the kit comprises one or more containers holding one or more naturally-occurring amino acids or amino acid analogs as desc ⁇ bed herein. In other embodiments, the kit comprises one or more containers holding one or more macrocycle-forming linkers as desc ⁇ bed herein. In yet other embodiments, the kit comprises one or more containers holding one or more amino acids or amino acid analogs as described herein, as well as one or more containers holding one or more macrocycle-forming linkers as described herein. [0098] For example, m some embodiments, the kit comprises a container holding at least one ammo acid or ammo acid analog, as described above, having an -SH moiety, the ammo acid optionally protected and suitable for the syntheses described herein.
  • the amino acid or amino acid analog is selected from the group consisting of L-cysteine, D-cysteine, L-N-methylcysteine, D-N-methylcysteine, L-homocysteme, D-homocysteine, L-N-methylhomocysteine, D-N-methylhomocysteine, omethyl-L-cysteine, ⁇ -methyl-D- cysteine, ⁇ -methyl-L-homocysteine, ⁇ -methyl-D-homocysteine, L-pemcillamine, D-penicillamine, L-N- methylpemcillamine, D-N-methylpenicillamine and all forms suitably protected for liquid or solid phase peptide synthesis.
  • the kit comprises a container holding at least one naturally-occurring amino acid, non-naturally-occurrmg amino acid, or amino acid analog bound to a solid support compatible with the syntheses desc ⁇ bed herein for peptidomimetic macrocycles.
  • the kit comp ⁇ ses a container holding a macrocycle-forming linker as described above.
  • the kit further comprises one or more containers holding reagents necessary for the macrocyclization reactions desc ⁇ bed herein, such as trifluoroacetic acid, liquid ammonia, NH 3 ZMeOH, NH 3 ZDMF, mercaptoethanol, hindered bases such as t ⁇ ethylamine or diisopropylethylamine, and guamdinium HCl.
  • the kit comp ⁇ ses one container holding an amino acid analog of the invention including a reactive -SH group in combination with a container holding a macrocycle-forming linker of the invention
  • the kit further comprises one or more containers holding reagents necessary for the macrocyclization reaction.
  • the kit comprises two containers, each of which holds a different amino acid analog of the invention including a reactive -SH group.
  • the kit further comprises one or more containers holding reagents necessary for the macrocyclization reaction and/or a macrocycle-forming linker of the invention.
  • a macrocycle of the invention has enhanced properties relative to a corresponding non-macrocychc polypeptide
  • a corresponding non-macrocyclic polypeptide is, for example, a precursor of a peptidomimetic macrocycle, such as a compound of Formula III which is converted into said macrocycle.
  • a corresponding non-macrocyclic polypeptide is a polypeptide sequence, such as a natural polypeptide sequence which has substantial sequence overlap with the macrocycle of the invention.
  • a correspon ing non-macrocyc ic po ypep i e can a so e a a e e na ura po ypep i e or peptidomimetic precursor.
  • labeling for example by fluorescent or radioactive labeling, is used if necessary m some of the assays described below. In such assays, both the macrocycle and the corresponding non-macrocyclic polypeptide are typically labeled by similar or functionally equivalent methods.
  • the percent helicity of unmodified pro-apoptotic BH3 domains are predominantly random coils in solution, with ⁇ -helical content usually under 25%.
  • Peptidomimetic macrocycles with optimized linkers possess, for example, an alpha-helicity that is at least two-fold greater than that of a corresponding non-macrocyclic polypeptide.
  • macrocycles of the invention will possess an alpha- helicity of greater than 50%.
  • the compounds are dissolved m aqueous 50 mM potassium phosphate solution at pH 7, or distilled H 2 O, to concentrations of 25-50 ⁇ M.
  • Circular dichroism (CD) spectra are obtained on a spectropolarimeter (e g , Jasco J-710) at 20 0 C using the following standard measurement parameters: wavelength, 190-260 nm; step resolution, 0.5 nm; speed, 20 nm/sec; accumulations, 10; response, 1 sec; bandwidth, 1 nm; path length, 0.1 cm.
  • ⁇ helical content of each peptide is calculated by dividing the mean residue elhpticity [ ⁇ ]222obs by the reported [ ⁇ ]222obs for a model helical decapeptide (Yang et al. (1986), Methods Enzymol. 130:208)).
  • a peptidomimetic macrocycle of the invention comprising a secondary structure such as an ⁇ -hehx exhibits, for example, a higher melting temperature than a corresponding non-macrocyclic polypeptide.
  • peptidomimetic macrocycles of the invention exhibit Tm of > 60 0 C representing a highly stable structure in aqueous solutions.
  • Peptidomimetic macrocycles and unmodified peptides are dissolved in distilled H 2 O at final concentration of 50 ⁇ M and the Tm is determined by measuring the change in elhpticity over a temperature range (4 to 95 0 C) on a spectropolarimeter (e g , Jasco J-710) using the following measurement parameters: wavelength 222nm; step resolution, 0.5 nm; speed, 20 nm/sec; accumulations, 10; response, 1 sec; bandwidth, 1 nm; temperature mcrease rate. l°C/mm; path length, 0.1 cm.
  • the amide bond of the peptide backbone is susceptible to hydrolysis by proteases, thereby rendering peptidic compounds vulnerable to rapid degradation in vivo. Peptide helix formation, however, typically bu ⁇ es the amide backbone and therefore may shield it from proteolytic cleavage.
  • the peptidomimetic macrocycles of the present invention are subjected to in vitro trypsin proteolysis to assess for any change in degradation rate compared to a corresponding non-macrocyclic polypeptide.
  • the peptidomimetic macrocycle and a corresponding non-macrocychc polypeptide are incubated with trypsin agarose and the reactions quenched at various time points by centrifugation and subsequent HPLC injection to quantitate the residual substrate by ultraviolet absorption at 280 nm.
  • the peptidomimetic macrocycle and precursor peptide (5 meg) are incubated with trypsin agarose (Pierce) (S/E ⁇ 125) for 0, 10, 20, 90, and 180 minutes. Reactions are quenched by tabletop centrifugation at high speed; remaining substrate in the isolated supernatant is quantified by HPLC-based peak detection at 280 nm.
  • the proteolytic reaction , - lXslope).
  • Peptidomimetic macrocycles with optimized linkers possess, for example, an ex vivo half-life that is at least two-fold greater than that of a corresponding non-macrocyclic polypeptide peptide, and possess an ex vivo half-life of 12 hours or more.
  • a peptidomimetic macrocycle and a corresponding non-macrocyclic polypeptide in a specific example, the corresponding natural polypeptide (2 meg) are incubated with fresh mouse, rat and human serum (2 mL) at 37°C for 0, 1, 2, 4, 8, and 24 hours.
  • the samples are extracted by transferring 100 ⁇ l of sera to 2 ml centrifuge tubes followed by the addition of 10 ⁇ L of 50 % formic acid and 500 ⁇ L acetonitrile and centrifugation at 14,000 RPM for 10 min at 4 ⁇ 2°C. The supernatants are then transferred to fresh 2 ml tubes and evaporated on Turbovap under N 2 ⁇ 10 psi, 37°C. The samples are reconstituted in lOO ⁇ L of 50:50 acetonitrile: water and submitted to LC-MS/MS analysis.
  • FPA fluorescence polarization assay
  • fluoresceinated peptidomimetic macrocycles 25 nM are incubated with the acceptor protein (25- 100OnM) in binding buffer (14OmM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room temperature. Binding activity ismeasured, for example, by fluorescence polarization on a Perkin-Elmer LS50B luminescence spectrophotometer. Kd values are determined by nonlinear regression analysis using
  • a peptidomimetic macrocycle of the invention show, for example, similar or lower Kd than a corresponding non-macrocyclic polypeptide.
  • Acceptor proteins for BH3-peptides such as BCL-2, BCL-X L , BAX or MCLl can be used in this assay.
  • Acceptor proteins for p53 peptides such as MDM2 or MDMX can be used in this assay.
  • a fluorescence polarization assay utilizing a fluoresceinated peptidomimetic macrocycle derived from a precursor peptide sequence is used, for example.
  • the FPA technique measures the molecular orientation and mobility using polarized light and fluorescent tracer.
  • fluorescent tracers e.g., FITC
  • molecules with high apparent molecular weights e.g.
  • FITC-labeled peptides bound to a large protein emit higher levels of polarized fluorescence due to their slower rates of rotation as compared to fluorescent tracers attached to smaller molecules (e.g. FITC-labeled peptides that are free in solution).
  • a compound that antagonizes the interaction between the fluoresceinated peptidomimetic macrocycle and an acceptor protein will be detected in a competitive binding FPA experiment.
  • pu a ive an agonis compoun s n o m an a uorescemated peptidomimetic macrocycle (25 nM) are incubated with the acceptor protein (50 nM) in binding buffer (14OmM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room temperature.
  • Antagonist binding activity ismeasured, for example, by fluorescence polarization on a Perkin-Elmer LS50B luminescence spectrophotometer. Kd values are determined by nonlinear regression analysis using Graphpad prism software.
  • Any class of molecule such as small organic molecules, peptides, oligonucleotides or proteins can be examined as putative antagonists in this assay.
  • Acceptor proteins for BH3-peptides such as BCL2, BCL- XL, BAX or MCLl can be used in this assay.
  • Acceptor proteins for p53 peptides such as MDM2 or MDMX can be used in this assay.
  • Extracts are centrifuged at 14,000 rpm for 15 minutes and supernatants collected and incubated with 10 ⁇ l goat anti-FITC antibody for 2 hrs, rotating at 4°C followed by further 2 hrs incubation at 4°C with protein A/G Sepharose (50 ⁇ l of 50% bead slurry). After quick centrifugation, the pellets are washed in lysis buffer containing increasing salt concentration (e.g., 150, 300, 500 mM). The beads are then re- equilibrated at 150 mM NaCl before addition of SDS-containing sample buffer and boiling.
  • increasing salt concentration e.g. 150, 300, 500 mM
  • the supernatants are optionally electrophoresed using 4%-12% gradient Bis-Tris gels followed by transfer into Immobilon-P membranes. After blocking, blots are optionally incubated with an antibody that detects FITC and also with one or more antibodies that detect proteins that bind to the peptidomimetic macrocycle, including BCL2, MCLl, BCL-XL, Al, BAX, BAK, MDM2 or MDMX.
  • a peptidomimetic macrocycle is, for example, more cell permeable compared to a corresponding non- macrocyclic polypeptide. In some embodiments, the peptidomimetic macrocycles are more cell permeable than a corresponding non-macrocyclic polypeptides.
  • Peptidomimetic macrocycles with optimized linkers possess, for example, cell permeability that is at least two-fold greater than a corresponding non- macrocyclic polypeptide, and often 20% or more of the applied peptide will be observed to have penetrated the cell after 4 hours.
  • To measure the cell permeability of peptidomimetic macrocycles and corresponding non-macrocyclic polypeptides intact cells are incubated with fluoresceinated peptidomimetic macrocycles or corresponding non-macrocyclic polypeptides (10 ⁇ M) for 4 hrs in serum free media at 37°C, washed twice with media and incubated with trypsin (0.25%) for 10 min at 37°C. The cells are washed again and resuspended in PBS. Cellular fluorescence is analyzed, for example, by using either a FACSCalibur flow cytometer or Cellomics' KineticScan ® HCS Reader.
  • the efficacy of certain peptidomimetic macrocycles is determined, for example, in cell-based killing assays using a variety of tumorigenic and non-tumorigenic cell lines and primary cells derived from human or mouse cell populations. Cell viability is monitored, for example, over 24-96 hrs of incubation with . . assays that measure cell viability are commercially available and are optionally used to assess the efficacy of the peptidomimetic macrocycles. In addition, assays that measure Annexin V and caspase activation are optionally used to assess whether the peptidomimetic macrocycles kill cells by activating the apoptotic machinery.
  • the compounds are, for example,administered to mice and/or rat by IV, IP, PO or inhalation routes at concentrations ranging from 0.1 to 50 mg/Kg and blood specimens withdrawn at 0', 5', 15', 30', 1 hr, 4 hrs, 8 hrs and 24 hours post- injection. Levels of intact compound in 25 ⁇ L of fresh serum are then measured by LC-MS/MS as above.
  • the compounds are, for example, given alone (IP, IV, PO, by inhalation or nasal routes) or in combination with sub-optimal doses of relevant chemotherapy (e.g., cyclophosphamide, doxorubicin, etoposide).
  • relevant chemotherapy e.g., cyclophosphamide, doxorubicin, etoposide.
  • 5 x 10 6 RS4; 11 cells (established from the bone marrow of a patient with acute lymphoblastic leukemia) that stably express luciferase are injected by tail vein in NOD-SCID mice 3 hrs after they have been subjected to total body irradiation.
  • Peptidomimetic macrocycles alone or in combination with sub-optimal doses of relevant chemotherapeutics agents are, for example, administered to leukemic mice (10 days after injection/day 1 of experiment, in bioluminescence of 14-16) by tail vein or IP routes at doses ranging from 0.1 mg/kg to 50 mg/kg for 7 to 21 days.
  • the mice are imaged throughout the experiment every other day and survival monitored daily for the duration of the experiment.
  • Expired mice are optionally subjected to necropsy at the end of the experiment.
  • DoHH2 a cell line derived from human follicular lymphoma, into NOD-SCID mice that stably expresses luciferase. These in vivo tests optionally generate preliminary pharmacokinetic, pharmacodynamic and toxicology data.
  • peptidomimetic macrocycles of the invention are selected and separated in treatment and one or more control groups, wherein the treatment group is administered a peptidomimetic macrocycle of the invention, while the control groups receive a placebo or a known anti-cancer drug.
  • the treatment safety and efficacy of the peptidomimetic macrocycles of the invention can thus be evaluated by performing comparisons of the patient groups with respect to factors such as survival and quality-of-life.
  • the patient group treated with a peptidomimetic macrocyle show improved long-term survival compared to a patient control group treated with a placebo.
  • the peptidomimetic macrocycles of the invention also include pharmaceutically acceptable derivatives or prodrugs thereof
  • pharmaceutically acceptable derivative means any pharmaceutically acceptable salt, ester, salt of an ester, pro-drug or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention
  • Particularly favored pharmaceutically acceptable derivatives are those that increase the bioavailability of the compounds of the invention when administered to a mammal (e g , by increasing absorption into the blood of an orally administered compound) or which increases delivery of the active compound to a biological compartment (e g , the bram or lymphatic system) relative to the parent species
  • Some pharmaceutically acceptable derivatives include a chemical group which increases aqueous solubility or active transport across the gastrointestinal mucosa
  • the peptidomimetic macrocycles of the invention are modified by covalently or non- covalently joining approp ⁇ ate functional groups to enhance selective biological properties
  • modifications include those which increase biological penetration into a given biological compartment (e g , blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism, and alter rate of excretion
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable morganic and organic acids and bases Examples of suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthal
  • the earner is a finely divided solid, which is in a mixture with the finely divided active component
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired
  • Suitable solid excrpients are carbohydrate or protein fillers include, but are not limited to sugars, including lactose, sucrose, mannitol, or sorbitol, starch from corn, wheat, rice, potato, or other plants, cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose, and gums including arable and tragacanth, as well as proteins such as gelatin and collagen
  • disintegrating or solubihzmg agents are added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate iqui orm prepara ions inc u e so u ions, suspensions
  • the pharmaceutical preparation is preferably in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • compositions of this invention comprise a combination of a peptidomimetic macrocycle and one or more additional therapeutic or prophylactic agents
  • both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
  • the additional agents are administered separately, as part of a multiple dose regimen, from the compounds of this invention.
  • those agents arepart of a single dosage form, mixed together with the compounds of this invention in a single composition.
  • the present invention provides novel peptidomimetic macrocycles that are useful in competitive binding assays to identify agents which bind to the natural ligand(s) of the proteins or peptides upon which the peptidomimetic macrocycles are modeled.
  • novel peptidomimetic macrocycles that are useful in competitive binding assays to identify agents which bind to the natural ligand(s) of the proteins or peptides upon which the peptidomimetic macrocycles are modeled.
  • labeled stabilized peptidomimetic macrocyles based on the p53 is used in an MDM2 binding assay along with small molecules that competitively bind to MDM2.
  • Competitive binding studies allow for rapid in vitro evaluation and determination of drug candidates specific for the p53/MDM2 system.
  • the invention further provides for the generation of antibodies against the peptidomimetic macrocycles.
  • these antibodies specifically bind both the peptidomimetic macrocycle and the p53 or BH3 precursor peptides upon which the peptidomimetic macrocycles are derived.
  • Such antibodies for example, disrupt the ⁇ 53/MDM2 or BH3/BCL-XL systems, respectively.
  • the present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant ⁇ e.g., insufficient or excessive) BCL-2 family member expression or activity ⁇ e.g., extrinsic or intrinsic apoptotic pathway abnormalities). It is believed that some BCL-2 type disorders are caused, at least in part, by an abnormal level of one or more BCL-2 family members ⁇ e.g., over or under expression), or by the presence of one or more BCL-2 family members exhibiting abnormal activity.
  • the present invention provides methods for treating or preventing hyperproliferative disease by interfering with the interaction or binding between p53 and MDM2 in tumor cells. These methods comprise administering an effective amount of a compound of the invention to a warm blooded anima , inc u ing a uman, or o umor ce s con a n ng w ype p .
  • e administration of the compounds of the present invention induce cell growth arrest or apoptosis.
  • the present invention is used to treat disease and/or tumor cells comprising elevated MDM2 levels. Elevated levels of MDM2 as used herein refers to MDM2 levels greater than those found in cells containing more than the normal copy number (2) of mdm2 or above about 10,000 molecules of
  • treatment is defined as the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disease, a symptom of disease or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease, the symptoms of disease or the predisposition toward disease.
  • he peptidomimetics macrocycles of the invention is used to treat, prevent, and/or diagnose cancers and neoplastic conditions.
  • cancer hyperproliferative and neoplastic
  • hyperproliferative and neoplastic disease states may be categorized as pathologic, i.e., characterizing or constituting a disease state, or may be categorized as non- pathologic, i.e., a deviation from normal but not associated with a disease state.
  • metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of breast, lung, liver, colon and ovarian origin.
  • Primary tumor types including but not limited to those of breast, lung, liver, colon and ovarian origin.
  • Primary tumor types including but not limited to those of breast, lung, liver, colon and ovarian origin.
  • Primary tumor types including but not limited to those of breast, lung, liver, colon and ovarian origin.
  • Primary tumor growth including but not limited to those of breast, lung, liver, colon and ovarian origin.
  • “Pathologic hyperproliferative" cells occur in disease states characterized by malignant tumor growth.
  • non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair.
  • cellular proliferative and/or differentiative disorders include cancer, e.g., carcinoma, sarcoma, or metastatic disorders.
  • the peptidomimetics macrocycles are novel therapeutic agents for controlling breast cancer, ovarian cancer, colon cancer, lung cancer, metastasis
  • cancers or neoplastic conditions include, but are not limited to, a fibrosarcoma, myosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, gastric cancer, esophageal cancer, rectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, uterine cancer, cancer of the head and neck, skin cancer, brain cancer, squamous cell carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma,
  • proliferative disorders include hematopoietic neoplastic disorders.
  • hematopoietic neoplastic disorders includes diseases involving hyperplastic/neoplastic cells of hematopoietic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof.
  • the diseases arise from poorly differentiated acute leukemias, e.g., erythroblastic leukemia and acu e mega aryo as ic eu emia i iona exemp ary mye oi isor ers inc u e, u are no imi e o, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus (1991), Cnt Rev Oncol /Hemotol 11 267-97); lymphoid malignancies include, but are not limited to acute lymphoblastic leukemia (ALL) which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM) Additional forms of malignant lymphomas include, but are not limited to ALL
  • Examples of cellular proliferative and/or differentiative disorders of the lung include, but are not limited to, bronchogenic carcinoma, including paraneoplastic syndromes, bronchioloalveolar carcinoma, neuroendocrine tumors, such as bronchial carcmoid, miscellaneous tumors, and metastatic tumors, pathologies of the pleura, including inflammatory pleural effusions, nonmflammatory pleural effusions, pneumothorax, and pleural tumors, including solitary fibrous tumors (pleural fibroma) and malignant mesothelioma [00138] Examples of cellular proliferative and/or differentiative disorders of the colon include, but are not limited to, non-neoplastic polyps, adenomas, familial syndromes, colorectal carcinogenesis, colorectal carcinoma, and carcmoid tumors
  • Examples of cellular proliferative and/or differentiative disorders of the liver include, but are not limited to, nodular hyperplasias, adenomas, and malignant tumors, including primary carcinoma of the liver and metastatic tumors.
  • Examples of cellular proliferative and/or differentiative disorders of the ovary include, but are not limited to, ovarian tumors such as, tumors of coelomic epithelium, serous tumors, mucinous tumors, endometrioid tumors, clear cell adenocarcinoma, cystadenof ⁇ broma, Brenner tumor, surface epithelial tumors, germ cell tumors such as mature (benign) teratomas, monodermal teratomas, immature malignant teratomas, dysgermmoma, endodermal sinus tumor, choriocarcinoma, sex cord-stomal tumors such as, granulosa- theca cell tumors, thecomafibromas, androblastomas, hill cell tumors, and gonadoblastoma, and metastatic tumors such as Krukenberg tumors [00141] In other or further embodiments, the peptidomimetics macrocycles described herein are used to
  • the anti-apoptotic peptidomimetics macrocycles of the invention are used to treat disorders such as those that lead to cell death associated with viral infection, e.g. , infection associated with infection with human immunodeficiency virus (HIV).
  • disorders such as those that lead to cell death associated with viral infection, e.g. , infection associated with infection with human immunodeficiency virus (HIV).
  • HIV human immunodeficiency virus
  • a wide variety of neurological diseases are characterized by the gradual loss of specific sets of neurons, and the anti-apoptotic peptidomimetics macrocycles of the invention are used, in some embodiments, in the treatment of these disorders.
  • disorders include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) retinitis pigmentosa, spinal muscular atrophy, and various forms of cerebellar degeneration.
  • ALS amyotrophic lateral sclerosis
  • apoptosis appears to be the mechanism of cell death.
  • hematologic diseases are associated with a decreased production of blood cells. These disorders include anemia associated with chronic disease, aplastic anemia, chronic neutropenia, and the myelodysplastic syndromes. Disorders of blood cell production, such as myelodysplastic syndrome and some forms of aplastic anemia, are associated with increased apoptotic cell death within the bone marrow. These disorders could result from the activation of genes that promote apoptosis, acquired deficiencies in stromal cells or hematopoietic survival factors, or the direct effects of toxins and mediators of immune responses.
  • myocardial infarctions and stroke Two common disorders associated with cell death are myocardial infarctions and stroke. In both disorders, cells within the central area of ischemia, which is produced in the event of acute loss of blood flow, appear to die rapidly as a result of necrosis. However, outside the central ischemic zone, cells die over a more protracted time period and morphologically appear to die by apoptosis. In other or further embodiments, the anti-apoptotic peptidomimetics macrocycles of the invention are used to treat all such disorders associated with undesirable cell death.
  • immunologic disorders that aretreated with the peptidomimetics macrocycles described herein include but are not limited to organ transplant rejection, arthritis, lupus, IBD, Crohn's disease, asthma, multiple sclerosis, diabetes, etc.
  • Some examples of neurologic disorders that are treated with the peptidomimetics macrocycles described herein include but are not limited to Alzheimer's Disease, Down's Syndrome, Dutch Type Hereditary Cerebral Hemorrhage Amyloidosis, Reactive Amyloidosis, Familial Amyloid Nephropathy with Urticaria and Deafness, Muckle-Wells Syndrome, Idiopathic Myeloma; Macroglobulinemia-Associated Myeloma, Familial Amyloid Polyneuropathy, Familial Amyloid Cardiomyopathy, Isolated Cardiac Amyloid, Systemic Senile Amyloidosis, Adult Onset Diabetes, Insulinoma, Isolated Atrial Amyloid, Medullary Carcinoma of the Thyroid, Familial Amyloidosis, Hereditary Cerebral Hemorrhage With Amyloidosis, Familial Amyloidotic Polyneuropathy, Scrapie, Creutzfeldt-Jacob Disease, Gerstmann Straussler-
  • peptidomimetics macrocycles described herein include but are not limited to diabetes, hypothyroidism, hypopituitarism, hypoparathyroidism, hypogonadism, etc.
  • cardiovascular disorders e.g., inflammatory disorders
  • cardiovascular disorders include, but are not limited to, atherosclerosis, myocardial infarction, stroke, thrombosis, aneurism, heart failure, ischemic heart disease, angina pectoris, sudden . .
  • yper ensive ear isease non-coronary vesse isease, suc as ar e ⁇ o osc erosis, sma vessel disease, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema and chronic pulmonary disease, or a cardiovascular condition associated with interventional procedures ("procedural vascular trauma"), such as restenosis following angioplasty, placement of a shunt, stent, synthetic or natural excision grafts, indwelling catheter, valve or other implantable devices
  • Preferred cardiovascular disorders include atherosclerosis, myocardial infarction, aneurism, and stroke.
  • Example 1 Synthesis of a peptidomimetic macrocycle
  • the target molecule is the BID-BH3 peptide with amino acids 12 and 16 replaced by Cysteine (see Table 1 and Table 6).
  • the Cysteine side chain thiols are then denvatized with 1,4-dibromobutane to form the bis-thioether peptidomimetic macrocycle
  • the peptidomimetic precursor was a polypeptide of the sequence DIIARHLACVGDCN L DRSI (where "N L " or "NIe” represent norleucme) synthesized at
  • the precursor polypeptide was acetylated at the amino terminus by treatment with ImM acetic anhydride and ImM dnsopropylethylamine (DIEA) in dimethylformamide (DMF) for 45 minutes Synthesis was done on rink amide resin (substitution 0 6mMol/g) with the cys 9 and cys 13 thiols protected with p-methoxyt ⁇ tyl
  • Mmt The Mmt groups were selectively deprotected with 1% TF A/4% TIS in dichloromethane (DCM) and the polypeptide was alkylated overnight at room temperature using 50 molar equivalents of 1 ,4-dibromobutane and 13 molar equivalents of dnsopropylethylamine (DIEA) in dichloroethane
  • DIEA dnsopropylethylamine
  • the peptide was then cleaved from the resin by treatment with 94% TFA 2% TIS 2% Anisole 2% H 2 O for 3 hours followed by filtration, concentration by rotary evaporation and precipitation with diethyl ether
  • the expected molecular weight of the final peptidomimetic macrocycle product is 2448 91
  • the observed molecular weight is 2445 5 by MALDI MS (see Figure 1) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.

Description

BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS
CROSS-REFERENCE
[0001] This application claims the benefit of U S. Provisional Application No. 60/874,819, filed December 14, 2006, which application is incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] Peptides are becoming increasingly important in drug discovery. Unmodified peptides often suffer from poor metabolic stability, poor cell penetrability, and promiscuous bindmg due to conformational flexibility. To improve these properties, researchers have generated cyclic peptides and peptidomimetics by a variety of methods, mcluding disulfide bond formation, amide bond formation, and carbon-carbon bond formation (Jackson et al. (1991), J Am Chem Soc. 113:9391-9392; Phelan et al. (1997), J Am Chem Soc. 119:455-
460; Taylor (2002), Biopolymers 66: 49-75; Brunei et al. (2005), Chem Commun. (20):2552-2554; Hiroshige ef α/. (1995), J. Λ/n Chem Soc. 117: 11590-11591; Blackwell et al. (199S), Angew Chem Int Ed. 37-3281-3284, Schafmeister et al. (2000), J Am Chem Soc. 122:5891-5892). Limitations of these methods include poor metabolic stability (disulfide and amide bonds), poor cell penetrability (disulfide and amide bonds), and the use of potentially toxic metals (carbon-carbon bonds).
SUMMARY OF THE INVENTION
[0003] The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use. In general, the synthesis of these peptidomimetic macrocycles involves (1) synthesizing a precursor peptide containing two free -SH moieties; and (2) contacting the precursor peptide with a bis-alkylating reagent to yield a novel peptidomimetic macrocycle. This general method permits the covalent linkage of at least two free thiolate moieties in a precursor peptide to yield novel compounds that exhibit improved biological properties such as structural stability, affinity for a target, resistance to proteolytic degradation and cell penetrance. In addition, this general method permits the rapid and selective incorporation of a broad diversity of moieties into the peptidomimetic macrocycle to permit the generation of a library of related macrocycles. This general method also permits the facile incorporation of labels (e g., radioisotopes, chemiluminescent or fluorescent labels) or therapeutic agents. [0004] Thus, in one aspect, the invention provides a peptidomimetic macrocycle of Formula (I):
Figure imgf000003_0001
wherein: each A, C, D, and E is independently a natural or non-natural ammo acid;
B is a natural or non-natural amino acid, amino acid
Figure imgf000003_0002
[-NH-L4-CO-], [-NH-L4-SO2-], or [-NH-L4-],
Ri and R2 are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo—, 3 s y rogen, a y , a eny , a yny , ary a y , eteroa y , cyc oa y , eterocyc oa y , cyc oa y a y , cycloaryl, or heterocycloaryl, unsubstituted or substituted with R5;
L], L2, L3 and L4 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [-R4-K-R4-In, each being unsubstituted or substituted with R5;
K is O, S, SO, SO2, CO, CO2, or CONR3; each R4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each R5 is independently halogen, alkyl, -OR6, -N(Re)2, -SR6, -SOR6, -SO2R6, -CO2R6, a fluorescent moiety, a radioisotope or a therapeutic agent; each R6 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
R7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R5 or part of a cyclic structure with a D residue;
Rg is — H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R5 or part of a cyclic structure with an E residue; v is an integer from 1-1000; w is an integer from 1-1000; x is an integer from 0-10; y is an integer from 0-10; z is an integer from 0-10; n is an integer from 1-5; and x+y+z is at least 3.
[0005] In some embodiments the peptidomimetic macrocycle comprises an α-helix and R8 is -H. In some embodiments, at least one of Ri and R2 is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo—. Alternatively, both Rj and R2 are independently alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-. In other embodiments, at least one OfR1 and R2 is alkyl, unsubstituted or substituted with halo—, or both R1 and R2 are independently alkyl, unsubstituted or substituted with halo—. In yet other embodiments, at least one OfR1 and R2 is methyl, or both R1 and R2 are methyl.
[0006] In some embodiments, at least one of D and E is a natural or unnatural amino acid substituted with a high molecular weight lipid or hydrocarbon. In other embodiments, at least one of D and E is attached to an additional macrocycle-forming linker of the formula [-L1-S-L2-S-L3-]. [0007] In some cases, a secondary structure of the peptidomimetic macrocycle is more stable than a corresponding secondary structure of a corresponding non-macrocyclic polypeptide. In some embodiments, the peptidomimetic macrocycle of the invention also comprises an α-helix. Such an α-helix, for example, comprises from 1 turn to 5 turns. Such an α-helix is, for example, more stable than an α-helix of a corresponding non-macrocyclic polypeptide. In some embodiments, [-L1-S-L2-S-L3-] spans from 1 turn to 5 turns of the α-helix, such as approximately 1, 2, 3, 4 or 5 turns of the α-helix. For example, - 1- - 2- - 3- spans approximate y turn o t e α- e ix xemp ary engt s ot [-L1-S-L2-S- 3-] are about 5 A to about 9 A per turn of the α-helix In some embodiments, the length of [-L1-S-L2-S-L3-] is approximately equal to the length of from about 5 carbon-carbon bonds to about 13 carbon-carbon bonds, or from about 7 carbon-carbon bonds to about 10 carbon-carbon bonds. In other embodiments, the macrocycle of the invention comprises a ring of about 17 atoms to 25 atoms
[0008] In yet other embodiments, the peptidomimetic macrocycle of the invention comprises an α-hehx which comprises about 2 turns. For example, the length of [-Li-S-L2-S-L3-] is approximately equal to the length of from about 8 carbon-carbon bonds to about 16 carbon-carbon bonds, or from about 10 carbon-carbon bonds to about 13 carbon-carbon bonds. In other embodiments, the macrocycle of the invention comprises a ring of about 29 atoms to about 37 atoms.
[0009] The present invention also provides a compound of Formula Ha-
PQ
Figure imgf000005_0001
R9 (Formula Ha) wherein.
Ri is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, L1 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [-R4-K-R4-Jn, unsubstituted or substituted with R5;
K is O, S, SO, SO2, CO, CO2, or CONR3,
R4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene, R5 is independently halogen, alkyl, -OR6, -N(Re)2, -SR6, -SOR6, -SO2R6, -CO2R6, a fluorescent moiety, a radioisotope or a therapeutic agent,
R6 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent,
R7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, or heterocyclyalkyl; R9 and R10 are independently -H or a protecting group suitable for peptide synthesis; n is an integer from 1 to 5;
Q is S, and
P is -H, -trityl, /7-methoxytrityl, -S f-butyl, or any other protecting group suitable for peptide synthesis; or
Q and P when taken together form a moiety capable of undergoing chemical transformation into an -SH group.
{0010] In some embodiments, Ri is alkyl, unsubstituted or substituted with halo—. In other embodiments, Ri is unsubstituted alkyl In yet other embodiments, R1 is methyl In still other embodiments, at least one of R9 and Rio is a protected group suitable for peptide synthesis.
[0011] The present invention also provides a kit comprising a) a compound of Formulas Ha and a compound of Formula lib
Figure imgf000006_0001
(Formula Ha) (Formula lib)
wherein: Ri is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;
R2 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;
Li and L3 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene or [-R4-K-R4-Jn, each being unsubstituted or substituted with R5;
K is O, S, SO, SO2, CO, CO2, or CONR3;
R4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each R5 is independently halogen, alkyl, -OR6, -N(R6J2, -SR6, -SOR6, -SO2R6, -CO2R6, -R6, a fluorescent moiety, a radioisotope, or a therapeutic agent; each R6 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent;
R7 and R8 are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, or heterocyclyalkyl;
R9 and Ri0 are each independently -H or any protecting group suitable for liquid or solid phase peptide synthesis;
Q is S;
P is — H, -trityl, p-methoxytrityl, -S f -butyl, or any other protecting group suitable for liquid or solid phase peptide synthesis; or Q and P when taken together form a moiety capable of undergoing chemical transformation into an -SH group; n is an integer from 1 to 5; and b) a macrocycle-forming linker of the structure:
X-L2-Y wherein L2 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [-R11-K-R11-Jn, each being unsubstituted or substituted with R12; each R11 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each R12 is independently halogen, alkyl, -OR13, -N(R6J13, -SR13, -SOR13, -SO2R13, -CO2R13, -R13, a fluorescent moiety, a radioisotope, or a therapeutic agent; each R13 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; and an are eac in epen en y a reac ive group capa e o reac ing wi a io group.
[0012] In some embodiments, R2 is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo. In specific such embodiments, R1 and R2 are alkyl. For example, Ri and R2 are methyl or trifluoromethyl.
[0013] A method for synthesizing a peptidomimetic macrocycle, the method comprising the step of contacting a peptidomimetic precursor of the Formula III:
Figure imgf000007_0001
(Formula III) with a compound formula X-L2-Y, wherein v, w, x, y, z, A, B, C, D, E, R1, R2, R7, R8, Li, L2, and L3 are as defined for the compound of formula I; and X and Y are each independently a reactive group capable of reacting with a thiol group; x+y+z is at least 3 ; and further wherein said contacting step results in a covalent linkage being formed between the two thiol groups in Formula III.
[0014] In some embodiments, performing a method of the invention results in the formation of a peptidomimetic macrocycle of Formula (I) as described herein.
[0015] In certain embodiments, at least one of Ri and R2 is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-. Alternatively, both R1 and R2 are independently alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-. In other embodiments, at least one OfR1 and R2 is alkyl, unsubstituted or substituted with halo-, or both Rj and R2 are independently alkyl, unsubstituted or substituted with halo-. In yet other embodiments, at least one of Ri and R2 is methyl, or both R1 and R2 are methyl.
[0016] In some embodiments, the peptidomimetic precursor is expressed in cells. The peptidomimetic precursor is also purified, in some embodiments, prior to the contacting step. The obtained peptidomimetic macrocycle is, in some instances, purified after the contacting step, and/or refolded after the contacting step.
[0017] The described method is, for example, performed in solution, or it performed on a solid support. The contacting step is, in some cases, performed in the presence of a target macromolecule that binds to the peptidomimetic precursor under conditions that favor said binding, or it is performed in the presence of a target macromolecule that binds preferentially to the peptidomimetic precursor under conditions that favor said binding. In some embodiments, the described method isapplied to synthesize a library of peptidomimetic macrocycles.
[0018] In some embodiments, a peptidomimetic macrocycle prepared by the method of the invention comprises an α-helix in aqueous solution. In other embodiments, the peptidomimetic macrocycle exhibits increased a- helical structure in aqueous solution compared to a corresponding non-macrocyclic polypeptide. In still other embodiments, the peptidomimetic macrocycle exhibits increased thermal stability, increased biological activity, increased resistance to proteolytic degradation, or increased ability to penetrate living cells compared to a corresponding non-macrocyclic polypeptide. In some embodiments, the two thiol moieties of the compound of Formula III are sidechains of an amino acid selected from the group consisting of L-cysteine, D-cysteine, α- methyl L-cysteine, and α-methyl D-cysteine. In certain , , , n n- natural amino acids [0019] The method described is, for example, performed in a solvent selected from the group consisting of protic solvent, aqueous solvent, organic solvent, and mixtures thereof In some embodiments, the solvent is DMF, dichloroethane, NH3, NH3/MeOH, NH3/DMF, or aqueous guamdinium-HCL In some embodiments, the solvent is also be a solvent that favors helix formation, such as water
[0020] In some embodiments of the compounds and methods described herein, L2 is an alkyl group In other embodiments, X and Y are independently chosen halogen groups such as Cl-, Br- or I—
BRIEF DESCRIPTION OF THE DRAWINGS [0021] The novel features of the invention are set forth with particularity in the appended claims A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, m which the principles of the invention are utilized, and the accompanying drawings of which [0022] FIGURE 1 shows a MALDI spectrum of a peptidomimetic macrocycle of the invention
DETAILED DESCRIPTION OF THE INVENTION
[0023] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only Numerous vaπations, changes, and substitutions will now occur to those skilled in the art without departing from the invention It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby
Definitions
[0024] As used herein, the term "macrocycle" refers to a molecule having a chemical structure including a ring or cycle formed by at least 9 covalently bonded atoms
[0025] As used herein, the term "peptidomimetic macrocycle" refers to a compound comprising a plurality of ammo acid residues joined by a plurality of peptide bonds and at least one macrocycle-forming linker which forms a macrocycle between the a carbon of one naturally-occurring ammo acid residue or non- naturally-occurring amino acid residue or amino acid analog residue and the a carbon of another naturally- occurπng amino acid residue or non-naturally-occurring ammo acid residue or amino acid analog residue. The peptidomimetic macrocycles optionally include one or more non-peptide bonds between one or more amino acid residues and/or amino acid analog residues, and optionally include one or more non-naturally- occurring amino acid residues or amino acid analog residues in addition to any which form the macrocycle
[0026] As used herein, the term "stability" refers to the maintenance of a defined secondary structure in solution by a peptide or peptidomimetic macrocycle of the invention as measured by circular dichroism, NMR or another biophysical measure, or resistance to proteolytic degradation in vitro or in vivo Non-limitmg examples of secondary structures contemplated in this invention are α-hehces, /3-turns, and /3-pleated sheets use erein, e erm e i i i y r r i nance o a e ica s ruc ure y a pep i e or peptidomimetic macrocycle of the invention as measured by circular dichroism. For example, in some embodiments, the peptidomimetic macrocycles of the invention exhibit at least a 1.25, 1.5, 1.75 or 2-fold increase in α-helicity as determined by circular dichroism compared to a corresponding non-macrocyclic polypeptide.
[0028] The term "α-amino acid" or simply "amino acid" refers to a molecule containing both an amino group and a carboxyl group bound to a carbon which is designated the α-carbon. Suitable amino acids include, without limitation, both the D-and L-isomers of the naturally-occurring amino acids, as well as non-naturally occurring amino acids prepared by organic synthesis or other metabolic routes. Unless the context specifically indicates otherwise, the term amino acid, as used herein, is intended to include amino acid analogs.
[0029] The term "naturally occurring amino acid" refers to any one of the twenty amino acids commonly found in peptides synthesized in nature, and known by the one letter abbreviations A, R, N, C, D, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y and V. [0030] The term "amino acid analog" refers to a molecule which is structurally similar to an amino acid and which can be substituted for an amino acid in the formation of a peptide or peptidomimetic macrocycle. Amino acid analogs include compounds which are structurally identical to an amino acid, as defined herein, except for the inclusion of one or more additional methylene groups between the amino and carboxyl group (e.g., α-amino /3-carboxy acids), or for the substitution of the amino or carboxy group by a similarly reactive group (e.g., substitution of the primary amine with a secondary or tertiary amine, or substitution or the carboxy group with an ester).
[0031] A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of a polypeptide (e.g., a BH3 domain or the p53 MDM2 binding domain) without abolishing or substantially altering its essential biological or biochemical activity (e.g., receptor binding or activation). An "essential" amino acid residue is a residue that, when altered from the wild-type sequence of the polypeptide, results in abolishing or substantially abolishing the polypeptide's essential biological or biochemical activity.
[0032] A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., K, R, H), acidic side chains (e.g., D, E), uncharged polar side chains (e.g., G, N, Q, S, T, Y, C), nonpolar side chains (e.g.,
A, V, L, I, P, F, M, W), beta-branched side chains (e.g., T, V, I) and aromatic side chains (e.g., Y, F, W, H). Thus, a predicted nonessential amino acid residue in a BH3 polypeptide, for example, is preferably replaced with another amino acid residue from the same side chain family.
[0033] The term "member" as used herein in conjunction with macrocycles or macrocycle-forming linkers refers to the atoms that form or can form the macrocycle, and excludes substituent or side chain atoms. By analogy, cyclodecane, 1,2-difluoro-decane and 1,3 -dimethyl cyclodecane are all considered ten-membered macrocycles as the hydrogen or fluoro substituents or methyl side chains do not participate in forming the macrocycle.
[0034] The symbol "■v " when used as part of a molecular structure refers to a single bond or a trans or cis double bond.
[0035] The term "amino acid side chain" refers to a moiety attached to the α-carbon in an amino acid. For example, the amino acid side chain for alanine is methyl, the amino acid side chain for phenylalanine is , , is carboxymethyl, the amino acid side chain for tyrosine is 4-hydroxyphenylmethyl, etc. Other non- naturally occurring amino acid side chains are also included, for example, those that occur in nature (e.g., an amino acid metabolite) or those that are made synthetically (e.g., an cx,a di-substituted amino acid). [0036] The term "polypeptide" encompasses two or more naturally or non-naturally-occurring amino acids joined by a covalent bond (e.g., an amide bond). Polypeptides as described herein include full length proteins (e.g., fully processed proteins) as well as shorter amino acids sequences (e.g., fragments of naturally occurring proteins or synthetic polypeptide fragments). [0037] The term "halo" or "halogen" refers to fluorine, chlorine, bromine or iodine or a radical thereof. [0038] The term "alkyl" refers to a hydrocarbon chain that is a straight chain or branched chain, containing the indicated number of carbon atoms. For example, Ci-Ci0 indicates that the group has from 1 to 10 (inclusive) carbon atoms in it. In the absence of any numerical designation, "alkyl" is a chain (straight or branched) having 1 to 20 (inclusive) carbon atoms in it. [0039] The term "alkylene" refers to a divalent alkyl (i.e., -R-). [0040] The term "alkenyl" refers to a hydrocarbon chain that is a straight chain or branched chain having one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C2-Ci0 indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. The term "lower alkenyl" refers to a C2-Ce alkenyl chain. In the absence of any numerical designation, "alkenyl" is a chain (straight or branched) having 2 to 20 (inclusive) carbon atoms in it. [0041] The term "alkynyl" refers to a hydrocarbon chain that is a straight chain or branched chain having one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C2-Ci0 indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. The term "lower alkynyl" refers to a C2-Ce alkynyl chain. In the absence of any numerical designation, "alkynyl" is a chain (straight or branched) having 2 to 20 (inclusive) carbon atoms in it. [0042] The term "aryl" refers to a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring are substituted by a substituent. Examples of aryl groups include phenyl, naphthyl and the like. The term "arylalkyl" or the term "aralkyl" refers to alkyl substituted with an aryl. The term "arylalkoxy" refers to an alkoxy substituted with aryl. [0043] "Arylalkyl" refers to an aryl group, as defined above, wherein one of the aryl group's hydrogen atoms has been replaced with a C1-C5 alkyl group, as defined above. Representative examples of an arylalkyl group include, but are not limited to, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-ethylphenyl, 3- ethylphenyl, 4-ethylphenyl, 2-ρroρylρhenyl, 3-propylphenyl, 4-propylphenyl, 2-butylphenyl, 3- butylphenyl, 4-butylphenyl, 2-pentylphenyl, 3-pentylphenyl, 4-pentylphenyl, 2-isoρropylphenyl, 3- isopropylphenyl, 4-isopropylphenyl, 2-isobutylphenyl, 3-isobutylphenyl, 4-isobutylphenyl, 2-sec- butylphenyl, 3-sec-butylphenyl, 4-sec-butylρhenyl, 2-t-butylphenyl, 3-t-butylphenyl and 4-t-butylphenyl,
[0044] "Arylamido" refers to an aryl group, as defined above, wherein one of the aryl group's hydrogen atoms has been replaced with one or more -C(O)NH2 groups. Representative examples of an arylamido group include 2-C(O)NH2-phenyl, 3-C(O)NH2-phenyl, 4-C(O)NH2-phenyl, 2-C(O)NH2-pyridyl, 3-C(O)NH2-pyridyl, and 4-C(O)NH2-pyridyl, [0045] "Alkylheterocycle" refers to a Ci-C5 alkyl group, as defined above, wherein one of the Ci-C5 alkyl group's hydrogen atoms has been replaced with a heterocycle. Representative examples of an alkylheterocycle , , - - , - 2 2- , - ^ 2 2 , 2- morpholine, and -CH2CH2CH2-ImIdEZoIe.
[0046] "Alkylamido" refers to a C]-C5 alkyl group, as defined above, wherein one of the CrC5 alkyl group's hydrogen atoms has been replaced with a -C(O)NH2 group. Representative examples of an alkylamido group include, but are not limited to, -CH2-C(O)NH2, -CH2CH2-C(O)NH2, -CH2CH2CH2C(O)NH2, -
CH2CH2CH2CH2C(O)NH2, -CH2CH2CH2CH2CH2C(O)NH2, -CH2CH(C(O)NH2)CH3, - CH2CH(C(O)NH2)CH2CH3, -CH(C(O)NH2)CH2CH3 and -C(CH3)2CH2C(O)NH2.
[0047] "Alkanol" refers to a Cj-C5 alkyl group, as defined above, wherein one of the Ci-C5 alkyl group's hydrogen atoms has been replaced with a hydroxyl group. Representative examples of an alkanol group include, but are not limited to, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2CH2CH2
CH2CH2OH, -CH2CH(OH)CH3, -CH2CH(OH)CH2CH3, -CH(OH)CH3 and -C(CH3)2CH2OH.
[0048] "Alkylcarboxy" refers to a Ci-C5 alkyl group, as defined above, wherein one of the Ci-C5 alkyl group's hydrogen atoms has been replaced with a — COOH group. Representative examples of an alkylcarboxy group include, but are not limited to, -CH2COOH, -CH2CH2COOH, -CH2CH2CH2COOH, - CH2CH2CH2CH2COOH, -CH2CH(COOH)CH3, -CH2CH2CH2CH2CH2COOH, -CH2CH(COOH)CH2CH3, -
CH(COOH)CH2CH3 and -C(CH3)2CH2COOH.
[0049] The term "cycloalkyl" as employed herein includes saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, preferably 3 to 8 carbons, and more preferably 3 to 6 carbons, wherein the cycloalkyl group additionally is optionally substituted. Some cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. •
[0050] The term "heteroaryl" refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein O, 1, 2, 3, or 4 atoms of each ring aresubstituted by a substituent. Examples of heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like.
[0051] The term "heteroarylalkyl" or the term "heteroaralkyl" refers to an alkyl substituted with a heteroaryl. The term "heteroarylalkoxy" refers to an alkoxy substituted with heteroaryl. [0052] The term "heteroaryl" refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein O, 1, 2, 3, or 4 atoms of each ring aresubstituted by a substituent. Examples of heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like.
[0053] The term "heteroarylalkyl" or the term "heteroaralkyl" refers to an alkyl substituted with a heteroaryl. The term "heteroarylalkoxy" refers to an alkoxy substituted with heteroaryl.
[0054] The term "heterocyclyl" refers to a nonaromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms ifbicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of O, N, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 a oms o ea i ri u i u y a su s i uen xamp es o e erocyc y groups mc u e piperazmy , pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like [0055] The term "substiruents" refers to a group "substituted" on an alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl group at any atom of that group Suitable substituents include, without limitation, halo, hydroxy, mercapto, oxo, nitro, haloalkyl, alkyl, alkaryl, aryl, aralkyl, alkoxy, thioalkoxy, aryloxy, amino, alkoxycarbonyl, amido, carboxy, alkanesulfonyl, alkylcarbonyl, and cyano groups
[0056] In some embodiments, the compounds of this invention contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures All such isomeric forms of these compounds are included in the present invention unless expressly provided otherwise In some embodiments, the compounds of this invention are also represented in multiple tautomeπc forms, in such instances, the invention includes all tautomeric forms of the compounds described herein (e.g , if alkylation of a ring system results m alkylation at multiple sites, the invention includes all such reaction products) All such isomenc forms of such compounds are included in the present invention unless expressly provided otherwise All crystal forms of the compounds described herein are included m the present invention unless expressly provided otherwise
[0057] As used herein, the terms "increase" and "decrease" mean, respectively, to cause a statistically significantly
(ι e , p < 0 1) increase or decrease of at least 5% [0058] As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values withm that range Thus, for a variable which is inherently discrete, the variable is equal to any integer value within the numerical range, including the end-points of the range Similarly, for a variable which is inherently continuous, the variable is equal to any real value withm the numerical range, including the end-points of the range As an example, and without limitation, a variable which is described as having values between 0 and 2 takes the values 0, 1 or 2 if the variable is inherently discrete, and takes the values 0 0, 0 1, 0 01, 0 001, or any other real values >0 and < 2 if the variable is inherently continuous
[0059] As used herein, unless specifically indicated otherwise, the word "or" is used in the inclusive sense of
"and/or" and not the exclusive sense of "either/or " [0060] The details of one or more particular embodiments of the invention are set forth m the accompanying drawings and the description below Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims
Peptidomimetic Macrocycles of the Invention [0061] The present invention provides peptidomimetic macrocycles of Formula (I)
Figure imgf000012_0001
Formula I wherein each A, C, D, and E is independently a natural or non-natural amino acid, B is a natural or non-natural amino acid, amino acid
Figure imgf000013_0001
[-NH-L4-CO-], [-NH-L4-SO2-], or [-NH-L4-];
Ri and R2 are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; R3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R5;
L1, L2, L3 and L4 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [-R4-K-R4-Jn, each being unsubstituted or substituted with R5; K is O, S, SO, SO2, CO, CO2, or CONR3; each R4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each R5 is independently halogen, alkyl, -OR6, -N(Rg)2, -SR6, -SOR6, -SO2R6, -CO2R6, a fluorescent moiety, a radioisotope or a therapeutic agent; each R6 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
R7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R5> or part of a cyclic structure with a D residue; R8 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R5> or part of a cyclic structure with an E residue; v is an integer from 1-1000; w is an integer from 1-1000; x is an integer from 0-10; y is an integer from 0-10; z is an integer from 0-10; and n is an integer from 1-5.
[0062] In some embodiments of the invention, x+y+z is at least 3. In other embodiments of the invention, x+y+z is 3, 4, 5, 6, 7, 8, 9 or 10. Each occurrence of A, B, C, D or E in a macrocycle or macrocycle precursor of the invention is independently selected. For example, a sequence represented by the formula [A]x, when x is 3, encompasses embodiments where the amino acids are not identical, e.g. Gin— Asp— Ala as well as embodiments where the amino acids are identical, e.g. Gln-Gln-Gln. This applies for any value of x, y, or z in the indicated ranges. [0063] In some embodiments, the peptidomimetic macrocycle of the invention comprises a secondary structure which is an α-helix and Rg is -H, allowing intrahelical hydrogen bonding. [0064] In other embodiments, the length of the macrocycle-forming linker [-L1-S-L2-S L3-] as measured from a first Ca to a second Ca is selected to stabilize a desired secondary peptide structure, such as an α-helix formed by residues of the peptidomimetic macrocycle including, but not necessarily limited to, those between the first Ca to a second Co. , - . ,
A, B and/or C in the compound of Formula I include one or more α-helices. As a general matter, α-helices include between 3 and 4 amino acid residues per turn. In some embodiments, the α-helix of the peptidomimetic macrocycle includes 1 to 5 turns and, therefore, 3 to 20 amino acid residues. In specific embodiments, the α-helix includes 1 turn, 2 turns, 3 turns, 4 turns, or 5 turns. In some embodiments, the macrocycle-forming linker stabilizes an α-helix motif included within the peptidomimetic macrocycle. Thus, in some embodiments, the length of the macrocycle-forming linker [-L1-S-L2-S-L3-] from a first Ca to a second Ca is selected to increase the stability of an α-helix. In some embodiments, the macrocycle- forming linker spans from 1 turn to 5 turns of the α-helix. In some embodiments, the macrocycle-forming linker spans approximately 1 turn, 2 turns, 3 turns, 4 turns, or 5 turns of the α-helix. In some embodiments, the length of the macrocycle-forming linker is approximately 5 A to 9 A per turn of the α-helix, or approximately 6 A to 8 A per turn of the α-helix. Where the macrocycle-forming linker spans approximately 1 turn of an α-helix, the length is equal to approximately 5 carbon-carbon bonds to 13 carbon-carbon bonds, approximately 7 carbon-carbon bonds to 11 carbon-carbon bonds, or approximately 9 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 2 turns of an α-helix, the length is equal to approximately 8 carbon-carbon bonds to 16 carbon-carbon bonds, approximately 10 carbon-carbon bonds to 14 carbon-carbon bonds, or approximately 12 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 3 turns of an α-helix, the length is equal to approximately 14 carbon-carbon bonds to 22 carbon-carbon bonds, approximately 16 carbon-carbon bonds to 20 carbon- carbon bonds, or approximately 18 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 4 turns of an α-helix, the length is equal to approximately 20 carbon-carbon bonds to 28 carbon-carbon bonds, approximately 22 carbon-carbon bonds to 26 carbon-carbon bonds, or approximately 24 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 5 turns of an α-helix, the length is equal to approximately 26 carbon-carbon bonds to 34 carbon-carbon bonds, approximately 28 carbon-carbon bonds to 32 carbon-carbon bonds, or approximately 30 carbon-carbon bonds. Where the macrocycle-forming linker spans approximately 1 turn of an α-helix, the linkage contains approximately 4 atoms to 12 atoms, approximately 6 atoms to 10 atoms, or approximately 8 atoms. Where the macrocycle- forming linker spans approximately 2 turns of the α-helix, the linkage contains approximately 7 atoms to 15 atoms, approximately 9 atoms to 13 atoms, or approximately 11 atoms. Where the macrocycle-forming linker spans approximately 3 turns of the α-helix, the linkage contains approximately 13 atoms to 21 atoms, approximately 15 atoms to 19 atoms, or approximately 17 atoms. Where the macrocycle-forming linker spans approximately 4 turns of the α-helix, the linkage contains approximately 19 atoms to 27 atoms, approximately 21 atoms to 25 atoms, or approximately 23 atoms. Where the macrocycle-forming linker spans approximately 5 turns of the α-helix, the linkage contains approximately 25 atoms to 33 atoms, approximately 27 atoms to 31 atoms, or approximately 29 atoms. Where the macrocycle-forming linker spans approximately 1 turn of the α-helix, the resulting macrocycle forms a ring containing approximately 17 members to 25 members, approximately 19 members to 23 members, or approximately 21 members. Where the macrocycle-forming linker spans approximately 2 turns of the α-helix, the resulting macrocycle forms a ring containing approximately 29 members to 37 members, approximately 31 members to 35 members, or approximately 33 members. Where the macrocycle-forming linker spans approximately 3 turns of the α-helix, the resulting macrocycle forms a ring containing approximately 44 members to 52 members, approximately 46 members to 50 members, or approximately 48 members. Where the macrocyc e-i rmmg in er spans approxima e y urns o e α- e ix, e resulting macrocycle forms a ring containing approximately 59 members to 67 members, approximately 61 members to 65 members, or approximately 63 members. Where the macrocycle-forming linker spans approximately 5 turns of the a- helix, the resulting macrocycle forms a ring containing approximately 74 members to 82 members, approximately 76 members to 80 members, or approximately 78 members.
[0066] In other embodiments, D and/or E are further modified in order to facilitate cellular uptake. For example, lipidating or PEGylating a peptide facilitates in some embodiments cellular uptake, increase bioavailability, increase blood circulation, alter pharmacokinetics, decrease immunogenic ity and/or decrease the needed frequency of administration. [0067] The synthesis of the peptidomimetic macrocycles of the invention involves a multi-step process that features the (1) synthesis of a precursor peptide or peptidomimetic containing two free -SH moieties; and (2) then contacting the precursor with a bis-alkylating reagent to generate two new covalent bonds. [0068] Macrocycles or macrocycle precursors are synthesized, for example, by solution phase or solid-phase methods, and can contain both naturally-occurring and non-naturally-occurring amino acids. See, for example, Hunt, "The Non-Protein Amino Acids" in Chemistry and Biochemistry of the Amino Acids, edited by G.C. Barrett, Chapman and Hall, 1985. In some embodiments, the thiol moieties are the side chains of the amino acid residues L-cysteine, D-cysteine, α-methyl-L cysteine, α-methyl-D-cysteine, L- homocysteine, D-homocysteine, α-methyl-L-homocysteine or α-methyl-D -homocysteine. The bis- alkylating reagent is of the general formula X-L2-Y wherein L2 is a linker moiety and X and Y are leaving groups that are displaced by -SH moieties to form bonds with L2. In some embodiments, X and Y are halogens such as I, Br, or Cl. [0069] In one embodiment, the peptidomimetic macrocycle exhibits improved biological properties such as increased structural stability, increased affinity for a target, increased resistance to proteolytic degradation and/or increased cell penetrance when compared to the precursor peptide or peptidomimetic. In another embodiment, the peptidomimetic macrocycle comprises one or more α-helices in aqueous solutions and/or exhibits an increased degree of α-helicity when compared to the precursor peptide or peptidomimetic. The method provides a route towards the synthesis of a library of peptidomimetic macrocycles by varying the X-L2-Y reagent, and in some embodiments the linker element L2 is optimized to improve the biological or pharmacological properties of the resultant peptidomimetic macrocycle. [0070] In some embodiments, the macrocycle-forming linker increases cell permeability of the peptidomimetic macrocycle. Thus, in some embodiments, the macrocycle-forming linker increases the overall hydrophobicity of the peptidomimetic macrocycle relative to the precursor peptide or peptidomimetic. [0071] Any protein or polypeptide with a known primary amino acid sequence which contains a secondary structure believed to impart biological activity is the subject of the present invention. For example, the sequence of the polypeptide can be analyzed and the sulfhydryl containing amino acid analogs of the invention can be substituted at the appropriate positions. The appropriate positions are determined by ascertaining which molecular surface(s) of the secondary structure is (are) required for biological activity and, therefore, across which other surface(s) the macrocycle forming linkers of the invention can form a macrocycle without sterically blocking the surface(s) required for biological activity. Such determinations are made using methods such as X-ray crystallography of complexes between the secondary structure and a natural binding partner to visualize residues (and surfaces) critical for activity; by sequential mutagenesis of residues in the secondary structure to functionally identify residues (and surfaces) critical for activity; or y o er me o s y suc e ermina ions, e appropria e amino aci s are suostiruteα witn trie amino aci s analogs and macrocycle-forming linkers of the invention For example, for an α-hehcal secondary structure, one surface of the helix (e g , a. molecular surface extending longitudinally along the axis of the helix and radially 45-135° about the axis of the helix) may be required to make contact with another biomolecule in vivo or in vitro for biological activity In such a case, a macrocycle-forming linker is designed to link two α-carbons of the helix while extending longitudinally along the surface of the helix in the portion of that surface not directly required for activity In some embodiments of the invention, the peptide sequence is derived from the BCL-2 family of proteins The BCL-2 family is defined by the presence of up to four conserved BCL-2 homology (BH) domains designated BHl, BH2, BH3, and BH4, all of which include α-hehcal segments (Chittenden et αl (1995),
EMBO 14 5589, Wang et αl. (1996), Genes Dev 10 2859) Anti-apoptotic proteins, such as BCL-2 and BCL-XL, display sequence conservation in all BH domains. Pro-apoptotic proteins are divided into "multidomam" family members (e g , BAK, BAX), which possess homology in the BHl, BH2, and BH3 domains, and "BH3-domarn only" family members (e g , BID, BAD, BIM, BIK, NOXA, PUMA), that contain sequence homology exclusively in the BH3 amphipathic α-hehcal segment BCL-2 family members have the capacity to form homo- and heterodimers, suggesting that competitive binding and the ratio between pro- and anti-apoptotic protein levels dictates susceptibility to death stimuli. Anti-apoptotic proteins function to protect cells from pro-apoptotic excess, i e , excessive programmed cell death Additional "security" measures include regulating transcription of pro-apoptotic proteins and maintaining them as inactive conformers, requiring either proteolytic activation, dephosphorylation, or hgand-mduced conformational change to activate pro-death functions. In certain cell types, death signals received at the plasma membrane trigger apoptosis via a mitochondrial pathway The mitochondria can serve as a gatekeeper of cell death by sequestering cytochrome c, a critical component of a cytosolic complex which activates caspase 9, leading to fatal downstream proteolytic events Multidomam proteins such as BCL- 2/BCL-XL and BAK/BAX play dueling roles of guardian and executioner at the mitochondrial membrane, with their activities further regulated by upstream BH3-only members of the BCL-2 family. For example, BID is a member of the BH3-domam only family of pro-apoptotic proteins, and transmits death signals received at the plasma membrane to effector pro-apoptotic proteins at the mitochondrial membrane BID has the capability of interacting with both pro- and anti-apoptotic proteins, and upon activation by caspase 8, triggers cytochrome c release and mitochondrial apoptosis Deletion and mutagenesis studies determined that the amphipathic α-hehcal BH3 segment of pro-apoptotic family members functions as a death domain and thus represents a cπtical structural motif for interacting with multidomam apoptotic proteins Structural studies have demonstrated that the BH3 helix interacts with anti-apoptotic proteins by inserting into a hydrophobic groove formed by the interface of BH 1 , 2 and 3 domains Activated BID can be bound and sequestered by anti-apoptotic proteins (e g , BCL-2 and BCL-XL) and can trigger activation of the pro- apoptotic proteins BAX and BAK, leading to cytochrome c release and a mitochondrial apoptosis program BAD is also a BH3-domain only pro-apoptotic family member whose expression triggers the activation of BAX/BAK. In contrast to BID, however, BAD displays preferential binding to anti-apoptotic family members, BCL-2 and BCL-XL Whereas the BAD BH3 domain exhibits high affinity binding to BCL-2, BAD BH3 peptide is unable to activate cytochrome c release from mitochondria in vitro, suggesting that
BAD is not a direct activator of BAX/BAK Mitochondria that over-express BCL-2 are resistant to BID- induced cytochrome c release, but co-treatment with BAD can restore BID sensitivity. Induction of i y r u i er: isp acement oi BAΛ/HAA. activa ors, such as BID and BID-like proteins, from the BCL-2/BCL-XL binding pocket, or (2) selective occupation of the BCL-2/BCL-XL binding pocket by BAD to prevent sequestration of BID-like proteins by anti- apoptotic proteins. Thus, two classes of BH3-domain only proteins have emerged, BID-like proteins that directly activate mitochondrial apoptosis, and BAD-like proteins, that have the capacity to sensitize mitochondria to BID-like pro-apoptotics by occupying the binding pockets of multidomain anti-apoptotic proteins. Various α-helical domains of BCL-2 family member proteins amendable to the methodology disclosed herein have been disclosed (Walensky et al. (2004), Science 305:1466; and Walensky et al., U.S. Patent Publication No. 2005/0250680, the entire disclosures of which are incorporated herein by reference).
[0073] In other embodiments, the peptide sequence is derived from the tumor suppressor p53 protein which binds to the oncogene protein MDM2. The MDM2 binding site is localized within a region of the p53 tumor suppressor that forms an a helix. In U.S. Pat. No. 7,083,983, the entire contents of which are incorporated herein by reference, Lane et al. disclose that the region of ρ53 responsible for binding to MDM2 is represented approximately by amino acids 13-31 (PLSQETFSDLWKLLPENNV) of mature human P53 protein. Other modified sequences disclosed by Lane are also contemplated in the instant invention. Furthermore, the interaction of p53 and MDM2 has been discussed by Shair et al. (1997), Chem. & Biol. 4:791, the entire contents of which are incorporated herein by reference, and mutations in the p53 gene have been identified in virtually half of all reported cancer cases. As stresses are imposed on a cell, ρ53 is believed to orchestrate a response that leads to either cell-cycle arrest and DNA repair, or programmed cell death. As well as mutations in the p53 gene that alter the function of the p53 protein directly, ρ53 can be altered by changes in MDM2. The MDM2 protein has been shown to bind to p53 and disrupt transcriptional activation by associating with the transactivation domain of p53. For example, an 11 amino- acid peptide derived from the transactivation domain of p53 forms an amphipathic α-helix of 2.5 turns that inserts into the MDM2 crevice. Thus, in some embodiments, novel α-helix structures generated by the method of the present invention are engineered to generate structures that bind tightly to the helix acceptor and disrupt native protein-protein interactions. These structures are then screened using high throughput techniques to identify optimal small molecule peptides. The novel structures that disrupt the MDM2 interaction are useful for many applications, including, but not limited to, control of soft tissue sarcomas (which over-expresses MDM2 in the presence of wild type p53). These cancers are then, in some embodiments, held in check with small molecules that intercept MDM2, thereby preventing suppression of p53. Additionally, in some embodiments, small molecules disrupters of MDM2-p53 interactions are used as adjuvant therapy to help control and modulate the extent of the ρ53 dependent apoptosis response in conventional chemotherapy.
[0074] A non-limiting exemplary list of suitable peptides for use in the present invention is given below:
TABLE 1
Figure imgf000017_0001
Figure imgf000018_0001
1 Peptide sequences listed in Table 1 are human sequences which target the BH3 binding site and are implicated in cancers, autoimmune disorders, metabolic diseases and other human disease conditions.
TABLE 21
Figure imgf000018_0002
Figure imgf000019_0001
'Peptide sequences listed in Table 2 are human sequences which target the BH3 binding site and are implicated in cancers, autoimmune disorders, metabolic diseases and other human disease conditions.
TABLE 31
Figure imgf000019_0002
'Peptide sequences listed in Table 3 are human sequences which target the p53 binding site of mdm2/x and are implicated in cancers.
TABLE 41
Figure imgf000019_0003
Figure imgf000020_0001
'Peptide sequences listed in Table 4 are sequences which target human G protein-coupled receptors and are implicated in numerous human disease conditions (Tyndall, J.D.A. et al. Chem. Rev. 2005, 105, 793-826).
Methods of synthesizing the peptidomimetic macrocycles of the invention
(00751 Methods of synthesizing the peptidomimetic macrocycles of the invention are disclosed herein. Alternative but equivalent protecting groups, leaving groups or reagents are substituted, and certain of the synthetic steps are performed in alternative sequences or orders to produce the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein include, for example, those such as described in Larock, Comprehensive Organic Transformations, VCH Publishers (1989); Greene and Wuts, Protective Groups in Organic Synthesis, 2d. Ed. , John Wiley and Sons (1991); Fieser and Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.
[0076] The peptidomimetic macrocycles of the invention are made, for example, by chemical synthesis methods, such as described in Fields et al., Chapter 3 in Synthetic Peptides: A User's Guide, ed. Grant, W. H. Freeman & Co., New York, N. Y., 1992, p. 77. Hence, for example, peptides are synthesized using the automated Merrifield techniques of solid phase synthesis with the amine protected by either tBoc or Fmoc chemistry using side chain protected amino acids on, for example, an automated peptide synthesizer (e.g., Applied Biosystems (Foster City, CA), Model 430A, 431, or 433). [0077] One manner of producing the precursor peptides and peptidomimetics described herein uses solid phase peptide synthesis (SPPS). The C-terminal amino acid is attached to a cross-linked polystyrene resin via an acid labile bond with a linker molecule. This resin is insoluble in the solvents used for synthesis, making it relatively simple and fast to wash away excess reagents and by-products. The N-terminus is protected with the Fmoc group, which is stable in acid, but removable by base. Side chain functional groups are protected as necessary with base stable, acid labile groups. [0078] Longer precursor peptides are produced, for example, by conjoining individual synthetic peptides using native chemical ligation. Alternatively, the longer synthetic peptides are biosynthesized by well known recombinant DNA and protein expression techniques. Such techniques are provided in well-known standard manuals with detailed protocols. To construct a gene encoding a precursor peptide of this invention, the amino acid sequence is reverse translated to obtain a nucleic acid sequence encoding the amino acid sequence, preferably with codons that are optimum for the organism in which the gene is to be expressed. Next, a synthetic gene is made, typically by synthesizing oligonucleotides which encode the peptide and any regulatory elements, if necessary. The synthetic gene is inserted in a suitable cloning vector and transfected into a host cell. The peptide is then expressed under suitable conditions appropriate for the selected expression system and host. The peptide is purified and characterized by standard methods. [0079] The precursor peptides and peptidomimetics are made, for example, in a high-throughput, combinatorial fashion using, for example, a high-throughput polychannel combinatorial synthesizer {e.g., Model Apex 396 multichannel peptide synthesizer from AAPPTEC, Inc., Louisville, KY). ie iscussion e ow is o ere i us ra e cer ain o e iver me v u e in assem ing the compounds of the invention. However, the discussion is not intended to limit the scope of reactions or reaction sequences that are useful in preparing the compounds of the present invention. The following synthetic schemes are provided solely to illustrate the present invention and are not intended to limit the scope of the invention, as described herein. To simplify the drawings, the illustrative schemes depict amino acid analogs derived from L-or D-cysteine, in which Li and L3 are both -(CH2)-. However, as noted throughout the detailed description above, many other amino acid analogs can be employed in which L1 and L3 can be independently selected from the various structures disclosed herein. The symbols "[AA]m'\ "[AA]n", "[AA]0" represent a sequence of amide bond-linked moieties such as natural or unnatural amino acids. As described previously, each occurrence of "AA" is independent of any other occurrence of "AA", and a formula such as "[AA]1n" encompasses, for example, sequences of non-identical amino acids as well as sequences of identical amino acids. Synthetic Scheme 1 :
Figure imgf000022_0001
Deprotect & cleave from solid support
Figure imgf000022_0002
[0082] In this first general method, the peptidomimetic precursor contains two -SH moieties and is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N-α-Fmoc amino acids such as N-α- Fmoc-S-trityl-L-cysteine or N-α-Fmoc-S-trityl-D-cysteine. Alpha-methylated versions of D-cysteine or L- cysteine are generated by known methods (Seebach et al. (1996), Angew. Chem. Int. Ed. Engl. 35:2708- 2748, and references therein) and then converted to the appropriately protected N-α-Fmoc-S-trityl monomers by known methods ("Bioorganic Chemistry: Peptides and Proteins", Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The precursor peptidomimetic is then deprotected and cleaved from the solid-phase resin by standard conditions {e.g. , strong acid such as 95% TFA). The precursor peptidomimetic is reacted as a crude mixture or is purified prior to reaction with X-L2-Y in organic or aqueous solutions. In some embodiments the alkylation reaction is performed under dilute conditions (i.e. 0.15 mmol/L) to favor macrocyclization and to avoid po ymeriza ion. n some em o imen s, e a y a ion reac ion is per orme in organic so u ions suc as liquid NH3 (Mosberg et al. (1985), J. ArαChem. Soc. 107:2986-2987; Szewczuk et al. (1992), Int. J. Peptide Protein Res. 40 :233-242), NH3TMeOH, or NH3/DMF (Or et al. (1991), J. Org. Chem. 56:3146- 3149). In other embodiments, the alkylation is performed in an aqueous solution such as 6M guanidinium HCL, pH 8 (Brunei et al. (2005), Chem. Commun. (20):2552-2554). In other embodiments, the solvent used for the alkylation reaction is DMF or dichloro ethane. Synthetic Scheme 2:
Figure imgf000023_0001
Deprotect R-S-Mmt
Figure imgf000023_0002
[0083] In this second general method, the precursor peptidomimetic contains two or more -SH moieties, of which two are specially protected to allow their selective deprotection and subsequent alkylation for macrocycle formation. The precursor peptidomimetic is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N-α-Fmoc amino acids such as N-α-Fmoc-S-p-methoxytrityl-L-cysteine or N-α- Fmoc-S-p-methoxytrityl-D-cysteine. Alpha-methylated versions of D-cysteine or L-cysteine are generated y nown me o s ee ac e a . , ngew. em. n . . ng . : - , an re erences therein) and then converted to the appropriately protected N-α-Fmoc-S-p-methoxytrityl monomers by known methods (Bioorganic Chemistry: Peptides and Proteins, Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The Mmt protecting groups of the peptidomimetic precursor are then selectively cleaved by standard conditions {e.g., mild acid such as 1% TFA in DCM). The precursor peptidomimetic is then reacted on the resin with X-L2-Y in an organic solution. For example, the reaction takes place in the presence of a hindered base such as diisopropylethylamine. In some embodiments, the alkylation reaction is performed in organic solutions such as liquid NH3 (Mosberg et al. (1985), J. Am.Chem. Soc. 107:2986-2987; Szewczuk et al. (1992), Int. J. Peptide Protein Res. 40 :233-242), NH3/MeOH or NH3/DMF (Or et al. (1991), J. Org. Chem. 56:3146- 3149). In other embodiments, the alkylation reaction is performed in DMF or dichloroethane. The peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions {e.g., strong acid such as 95% TFA). Synthetic Scheme 3:
Figure imgf000024_0001
1. Deprotect R-S-M mt
2. Cyclize
Me
Figure imgf000024_0002
[0084] In this third general method, the peptidomimetic precursor contains two or more -SH moieties, of which two are specially protected to allow their selective deprotection and subsequent alkylation for macrocycle formation. The peptidomimetic precursor is synthesized by solid-phase peptide synthesis (SPPS) using commercially available N-α-Fmoc amino acids such as N-α-Fmoc-S-/?-methoxytrityl-L-cysteine, N-α-
Fmoc-S-p-methoxytrityl-D-cysteine, N-α-Fmoc-S-S-t-butyl-L-cysteine, and N-α-Fmoc-S-S-t-butyl-D- cysteine. Alpha-methylated versions of D-cysteine or L-cysteine are generated by known methods (Seebach et al. (1996), Angew. Chem. Int. Ed. Engl. 35:2708-2748, and references therein) and then converted to the - - moc- -p- xy - - moc- - - - u yi monomers oy Known methods (Bioorganic Chemistry: Peptides and Proteins, Oxford University Press, New York: 1998, the entire contents of which are incorporated herein by reference). The S-S-tButyl protecting group of the peptidomimetic precursor is selectively cleaved by known conditions (e.g., 20% 2-mercaptoethanol in DMF, reference: Galande et at. (2005), J. Comb. Chem. l:\14-\ll). The precursor peptidomimetic is then reacted on the resin with a molar excess OfX-L2-Y in an organic solution. For example, the reaction takes place in the presence of a hindered base such as diisopropylethylamine. The Mmt protecting group of the peptidomimetic precursor is then selectively cleaved by standard conditions (e.g., mild acid such as 1% TFA in DCM). The peptidomimetic precursor is then cyclized on the resin by treatment with a hindered base in organic solutions. In some embodiments, the alkylation reaction is performed in organic solutions such as NH3/MeOH or NH3/DMF (Or et at. (1991), J. Org. Chem. 56:3146-3149). The peptidomimetic macrocycle is then deprotected and cleaved from the solid-phase resin by standard conditions (e.g., strong acid such as 95% TFA). Synthetic Scheme 4:
1. Biological H
2. Purification of peptide
Figure imgf000025_0001
[0085J In this fourth general method, the peptidomimetic precursor contains two L-cysteine moieties. The peptidomimetic precursor is synthesized by known biological expression systems in living cells or by known in vitro, cell-free, expression methods. The precursor peptidomimetic is reacted as a crude mixture or is purified prior to reaction with X-L2-Y in organic or aqueous solutions. In some embodiments the alkylation reaction is performed under dilute conditions (i.e. 0.15 mmol/L) to favor macrocyclization and to avoid polymerization. In some embodiments, the alkylation reaction is performed in organic solutions such as liquid NH3 (Mosberg et al. (1985), J. Am.Chem. Soc. 107:2986-2987; Szewczuk et al. (1992), Int. J. Peptide Protein Res. 40 :233-242), NH3/MeOH, or NH3/DMF (Or et al. (1991), J. Org. Chem. 56:3146- 3149). In other embodiments, the alkylation is performed in an aqueous solution such as 6M guanidinium HCL, pH 8 (Brunei et al. (2005), Chem. Commun. (20):2552-2554). In other embodiments, the alkylation is performed in DMF or dichloroethane. In another embodiment, the alkylation is performed in non- denaturing aqueous solutions, and in yet another embodiment the alkylation is performed under conditions that favor α-helical structure formation. In yet another embodiment, the alkylation is performed under conditions that favor the binding of the precursor peptidomimetic to another protein, so as to induce the formation of the bound or-helical conformation during the alkylation.
[0086] Various embodiments for X and Y are envisioned which are suitable for reacting with thiol groups. In general, each X or Y is independently be selected from the general category shown in Table 5. For example, X and Y are halides such as -Cl, -Br or -I.
TABLE 5: Examples of Reactive Groups Capable of Reacting with Thiol Groups and Resulting Linkages
Figure imgf000025_0002
: xamp es o eac ve roups apa e Reacting with Thiol Groups and Resulting Linkages
Figure imgf000026_0001
Table 6 shows exemplary macrocycles of the invention. For the examples shown in this table, a corresponding non-macrocyclic polypeptide is the BID BH3 polypeptide sequence fragment DIIRNIARHLAQVGDSMDRSI. "NL" represents norleucine and replaces a methionine residue. It is envisioned that similar linkers are used to synthesize peptidomimetic macrocycles based on the polypeptide sequences disclosed in Table 1 through Table 4.
Figure imgf000027_0001
Figure imgf000028_0001
Amino Acid Analogs The present invention contemplates the use of both naturally-occurring and non-naturally-occurring amino acids and amino acid analogs in the synthesis of the peptidomimetic macrocycles described above. Any amino acid or amino acid analog amenable to the synthetic methods employed for the synthesis of stable bis-sulfhydryl containing peptidomimetic macrocycles can be used in the present invention For example, cysteine is contemplated as a useful amino acid in the present invention However, sulfur containing amino acids other than cysteine that contain a different amino acid side cham are also useful in the invention For example, cysteine contains one methylene unit between the α-carbon of the amino acid and the terminal — _ o e amino aci si e c ain. e inven ion a so con emp a es e use o amino aci s wi mu ip e methylene units between the α-carbon and the terminal -SH. Non-limiting examples include L- homocysteine, D-homocysteine, α-methyl-L-homocysteine and α-methyl-D-homocysteine. In some embodiments the amino acids and amino acid analogs are of the D- configuration. In other embodiments they are of the L- configuration. In some embodiments, some of the amino acids and amino acid analogs contained in the peptidomimetic are of the D- configuration while some of the amino acids and amino acid analogs are of the L- configuration. In some embodiments the amino acid analogs are α,α-disubstituted, such as α-methyl-L-cysteine and α-methyl-D-cysteine. In some embodiments the amino acid analogs are N- alkylated, e.g. , N-methyl-L-cysteine and N-methyl-D-cysteine. [0089] Other amino acid analogs useful in the present invention for forming peptidomimetic macrocycles are compounds of Formula Ha:
PQ
Figure imgf000029_0001
R9 (Formula Ha) wherein:
Ri is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl; Li is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [-R4-K-R4-Jn, unsubstituted or substituted with R5;
K is O, S, SO, SO2, CO, CO2, or CONR3;
R4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; R5 is independently halogen, alkyl, -OR6, -N(Rg)2, -SR6, -SOR6, -SO2R6, -CO2R6, a fluorescent moiety, a radioisotope or a therapeutic agent;
R6 is independently — H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
R7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, or heterocyclyalkyl; Rg and Rio are independently — H or a protecting group suitable for peptide synthesis; n is an integer from 1 to 5;
Q is S; and
P is — H, -trityl, /7-methoxytrityl, -S ^-butyl, or any other protecting group suitable for peptide synthesis; or
Q and P when taken together form a moiety capable of undergoing chemical transformation into an -SH group.
[0090] In some embodiments either the -NH or the -SH moieties of the amino acid are protected. In other embodiments both moieties are protected, for example protecting groups for either the -NH and the -SH moieties in amino acids. Non-limiting examples of such -NH protecting groups are -Fmoc and -Boc. Non- limiting examples of -SH protecting groups are -trityl, /?-methoxytrityl, and -S 2-butyl. In other embodiments, the amino acid is not protected prior to synthesis of the peptidomimetic macrocycle. a e . xemp ary am no ac s o t e nvent on.
Figure imgf000030_0001
Macrocycle-forming linkers [0091] The present invention includes macrocycle-forming linkers used to link two or more -SH moieties in the peptidomimetic precursors to form the peptidomimetic macrocycles of the invention. As described above, the macrocycle-forming linkers impart conformational rigidity, increased metabolic stability and/or increased cell penetrability. Furthermore, in some embodiments, the macrocycle-forming linkages stabilize the α-helical secondary structure of the peptidomimetic macrocyles. The macrocycle-forming linkers are of the formula X-L2-Y, wherein both X and Y are the same or different moieties, as defined above. Both X and Y have the chemical characteristics that allow one macrocycle-forming linker -L2- to bis alkylate the bis-sulfhydryl containing peptidomimetic precursor. As defined above, the linker -L2- includes alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene, or -R4-K-R4-, all of which can be optionally substituted with an R5 group, as defined above. Furthermore, one to three carbon atoms withm the macrocycle-forming linkers -L2-, other than the carbons attached to the -SH of the sulfhydryl containing amino acid, are optionally substituted with a heteroatom such as N, S or O.
[0092] The L2 component of the macrocycle-forming linker X-L2-Y may be varied m length depending on, among other things, the distance between the positions of the two amino acid analogs used to form the peptidomimetic macrocycle. Furthermore, as the lengths of L] and/or L3 components of the macrocycle- forming linker are varied, the length of L2 can also be varied in order to create a linker of appropriate overall length for forming a stable peptidomimetic macrocycle. For example, if the amino acid analogs use are varie y a ng an a ona me y ene un to eac o i an 3, t e engt o 2 are ecrease in length by the equivalent of approximately two methylene units to compensate for the increased lengths
[0093] In some embodiments, L2 is an alkylene group of the formula — (CH2),!- > where n is an integer between about 1 and about 15. For example, n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In other embodiments, L2 is an alkenylene group. In still other embodiments, L2 is an aryl group. [0094] Table X shows additional embodiments of X-L2-Y groups.
Table 8. Exemplary X-L2-Y groups of the invention.
O Y
X O
Figure imgf000031_0001
Figure imgf000031_0002
Each X and Y in this Table, are, for example, independently Cl-, Br- or I—.
Kits [0095] In another aspect, the present invention further provides kits comprising amino acid analogs and/or macrocycle- forming linkers as described herein. [0096] In one embodiment the kit contains a) a compound of Formulas Ha and a compound of Formula lib:
Figure imgf000032_0001
Ha lib
wherein Ri is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;
R2 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;
Li and L3 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene or [-R4-K-R4-Jn, each being unsubstituted or substituted with R5;
K is O, S, SO, SO2, CO, CO2, or CONR3;
R4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each R5 is independently halogen, alkyl, -OR6, -N(Rg)2, -SR6, -SOR6, -SO2R6, -CO2R6, -R6, a fluorescent moiety, a radioisotope, or a therapeutic agent; each R6 is independently — H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent;
R7 and R8 are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, or heterocyclyalkyl;
R9 and Ri0 are each independently -H or any protecting group suitable for liquid or solid phase peptide synthesis;
Q is S;
P is -H, -trityl, p-methoxytrityl, -S t-butyl, or any other protecting group suitable for liquid or solid phase peptide synthesis; or Q and P when taken together form a moiety capable of undergoing chemical transformation into an -SH group; n is an integer from 1 to 5; and b) a macrocycle-forming linker of the structure:
X-L2-Y wherein L2 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [-Rn-K-Rn-]n, each being unsubstituted or substituted with R12; each R11 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each Ri2 is independently halogen, alkyl, -ORn, -N(Re)n, -SRn, -SORn, -SO2R13, -CO2R13, -Rn, a fluorescent moiety, a radioisotope, or a therapeutic agent; 13 - , , , , , , , heterocyclyalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; and
X and Y are each independently a reactive group capable of reacting with a thiol group.
[0097] In some embodiments, the kit comprises one or more containers holding one or more naturally-occurring amino acids or amino acid analogs as descπbed herein. In other embodiments, the kit comprises one or more containers holding one or more macrocycle-forming linkers as descπbed herein. In yet other embodiments, the kit comprises one or more containers holding one or more amino acids or amino acid analogs as described herein, as well as one or more containers holding one or more macrocycle-forming linkers as described herein. [0098] For example, m some embodiments, the kit comprises a container holding at least one ammo acid or ammo acid analog, as described above, having an -SH moiety, the ammo acid optionally protected and suitable for the syntheses described herein. In some embodiments, the amino acid or amino acid analog is selected from the group consisting of L-cysteine, D-cysteine, L-N-methylcysteine, D-N-methylcysteine, L-homocysteme, D-homocysteine, L-N-methylhomocysteine, D-N-methylhomocysteine, omethyl-L-cysteine, α-methyl-D- cysteine, α-methyl-L-homocysteine, α-methyl-D-homocysteine, L-pemcillamine, D-penicillamine, L-N- methylpemcillamine, D-N-methylpenicillamine and all forms suitably protected for liquid or solid phase peptide synthesis.
[0099] In some embodiments, the kit comprises a container holding at least one naturally-occurring amino acid, non-naturally-occurrmg amino acid, or amino acid analog bound to a solid support compatible with the syntheses descπbed herein for peptidomimetic macrocycles.
[00100] In some embodiments, the kit compπses a container holding a macrocycle-forming linker as described above. In some embodiments, the kit further comprises one or more containers holding reagents necessary for the macrocyclization reactions descπbed herein, such as trifluoroacetic acid, liquid ammonia, NH3ZMeOH, NH3ZDMF, mercaptoethanol, hindered bases such as tπethylamine or diisopropylethylamine, and guamdinium HCl.
[00101] In some embodiments, the kit compπses one container holding an amino acid analog of the invention including a reactive -SH group in combination with a container holding a macrocycle-forming linker of the invention Optionally, the kit further comprises one or more containers holding reagents necessary for the macrocyclization reaction. In other embodiments, the kit comprises two containers, each of which holds a different amino acid analog of the invention including a reactive -SH group. Optionally, the kit further comprises one or more containers holding reagents necessary for the macrocyclization reaction and/or a macrocycle-forming linker of the invention.
Assays [00102] The properties of the peptidomimetic macrocycles of the invention are assayed, for example, by using the methods described below. In some embodiments, a macrocycle of the invention has enhanced properties relative to a corresponding non-macrocychc polypeptide A corresponding non-macrocyclic polypeptide is, for example, a precursor of a peptidomimetic macrocycle, such as a compound of Formula III which is converted into said macrocycle. Alternatively, a corresponding non-macrocyclic polypeptide is a polypeptide sequence, such as a natural polypeptide sequence which has substantial sequence overlap with the macrocycle of the invention. Numerous examples of natural polypeptides corresponding to the macrocyclic polypeptide are shown m Tables 1, 2, 3 and 4. J n genera , a correspon ing non-macrocyc ic po ypep i e can a so e a a e e na ura po ypep i e or peptidomimetic precursor. Such labeling, for example by fluorescent or radioactive labeling, is used if necessary m some of the assays described below. In such assays, both the macrocycle and the corresponding non-macrocyclic polypeptide are typically labeled by similar or functionally equivalent methods.
Assay to Determine Alpha helicitv.
[00104] The percent helicity of unmodified pro-apoptotic BH3 domains are predominantly random coils in solution, with α-helical content usually under 25%. Peptidomimetic macrocycles with optimized linkers, on the other hand, possess, for example, an alpha-helicity that is at least two-fold greater than that of a corresponding non-macrocyclic polypeptide. In some embodiments, macrocycles of the invention will possess an alpha- helicity of greater than 50%. To assay the helicity of peptidomimetic macrocyles of the invention, such as BH3 domam-based macrocycles, the compounds are dissolved m aqueous 50 mM potassium phosphate solution at pH 7, or distilled H2O, to concentrations of 25-50 μM. Circular dichroism (CD) spectra are obtained on a spectropolarimeter (e g , Jasco J-710) at 200C using the following standard measurement parameters: wavelength, 190-260 nm; step resolution, 0.5 nm; speed, 20 nm/sec; accumulations, 10; response, 1 sec; bandwidth, 1 nm; path length, 0.1 cm. The α helical content of each peptide is calculated by dividing the mean residue elhpticity [Φ]222obs by the reported [Φ]222obs for a model helical decapeptide (Yang et al. (1986), Methods Enzymol. 130:208)).
Assay to Determine Melting Temperature (Tm). [OOIOS] A peptidomimetic macrocycle of the invention comprising a secondary structure such as an α-hehx exhibits, for example, a higher melting temperature than a corresponding non-macrocyclic polypeptide.
Typically peptidomimetic macrocycles of the invention exhibit Tm of > 600C representing a highly stable structure in aqueous solutions. Peptidomimetic macrocycles and unmodified peptides are dissolved in distilled H2O at final concentration of 50 μM and the Tm is determined by measuring the change in elhpticity over a temperature range (4 to 95 0C) on a spectropolarimeter (e g , Jasco J-710) using the following measurement parameters: wavelength 222nm; step resolution, 0.5 nm; speed, 20 nm/sec; accumulations, 10; response, 1 sec; bandwidth, 1 nm; temperature mcrease rate. l°C/mm; path length, 0.1 cm.
Protease Resistance Assay [00106] The amide bond of the peptide backbone is susceptible to hydrolysis by proteases, thereby rendering peptidic compounds vulnerable to rapid degradation in vivo. Peptide helix formation, however, typically buπes the amide backbone and therefore may shield it from proteolytic cleavage. The peptidomimetic macrocycles of the present invention are subjected to in vitro trypsin proteolysis to assess for any change in degradation rate compared to a corresponding non-macrocyclic polypeptide. The peptidomimetic macrocycle and a corresponding non-macrocychc polypeptide are incubated with trypsin agarose and the reactions quenched at various time points by centrifugation and subsequent HPLC injection to quantitate the residual substrate by ultraviolet absorption at 280 nm. Briefly, the peptidomimetic macrocycle and precursor peptide (5 meg) are incubated with trypsin agarose (Pierce) (S/E ~125) for 0, 10, 20, 90, and 180 minutes. Reactions are quenched by tabletop centrifugation at high speed; remaining substrate in the isolated supernatant is quantified by HPLC-based peak detection at 280 nm. The proteolytic reaction , , - lXslope).
Ex Vivo Stability Assay.
[00107] Peptidomimetic macrocycles with optimized linkers possess, for example, an ex vivo half-life that is at least two-fold greater than that of a corresponding non-macrocyclic polypeptide peptide, and possess an ex vivo half-life of 12 hours or more. For ex vivo serum stability studies, a peptidomimetic macrocycle and a corresponding non-macrocyclic polypeptide (in a specific example, the corresponding natural polypeptide) (2 meg) are incubated with fresh mouse, rat and human serum (2 mL) at 37°C for 0, 1, 2, 4, 8, and 24 hours. To determine the level of intact compound, the following procedure is used: The samples are extracted by transferring 100 μl of sera to 2 ml centrifuge tubes followed by the addition of 10 μL of 50 % formic acid and 500μL acetonitrile and centrifugation at 14,000 RPM for 10 min at 4 ± 2°C. The supernatants are then transferred to fresh 2 ml tubes and evaporated on Turbovap under N2 < 10 psi, 37°C. The samples are reconstituted in lOOμL of 50:50 acetonitrile: water and submitted to LC-MS/MS analysis.
In vitro Binding Assays. [00108] To assess the binding and affinity of peptidomimetic macrocycles and precursor peptides to acceptor proteins, a fluorescence polarization assay (FPA) isused, for example. The FPA technique measures the molecular orientation and mobility using polarized light and fluorescent tracer. When excited with polarized light, fluorescent tracers {e.g. , FITC) attached to molecules with high apparent molecular weights (e.g. FITC-labeled peptides bound to a large protein) emit higher levels of polarized fluorescence due to their slower rates of rotation as compared to fluorescent tracers attached to smaller molecules (e.g. FITC- labeled peptides that are free in solution).
[00109] For example, fluoresceinated peptidomimetic macrocycles (25 nM) are incubated with the acceptor protein (25- 100OnM) in binding buffer (14OmM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room temperature. Binding activity ismeasured, for example, by fluorescence polarization on a Perkin-Elmer LS50B luminescence spectrophotometer. Kd values are determined by nonlinear regression analysis using
Graphpad Prism software. A peptidomimetic macrocycle of the invention show, for example, similar or lower Kd than a corresponding non-macrocyclic polypeptide.
[00110] Acceptor proteins for BH3-peptides such as BCL-2, BCL-XL, BAX or MCLl can be used in this assay. Acceptor proteins for p53 peptides such as MDM2 or MDMX can be used in this assay.
In vitro Displacement Assays To Characterize Antagonists of Peptide-Protein Interactions.
[00111] To assess the binding and affinity of compounds that antagonize the interaction between a peptide (e.g. a BH3 peptide or a p53 peptide) and an acceptor protein, a fluorescence polarization assay (FPA) utilizing a fluoresceinated peptidomimetic macrocycle derived from a precursor peptide sequence is used, for example. The FPA technique measures the molecular orientation and mobility using polarized light and fluorescent tracer. When excited with polarized light, fluorescent tracers (e.g., FITC) attached to molecules with high apparent molecular weights (e.g. FITC-labeled peptides bound to a large protein) emit higher levels of polarized fluorescence due to their slower rates of rotation as compared to fluorescent tracers attached to smaller molecules (e.g. FITC-labeled peptides that are free in solution). A compound that antagonizes the interaction between the fluoresceinated peptidomimetic macrocycle and an acceptor protein will be detected in a competitive binding FPA experiment. z or examp e, pu a ive an agonis compoun s n o m an a uorescemated peptidomimetic macrocycle (25 nM) are incubated with the acceptor protein (50 nM) in binding buffer (14OmM NaCl, 50 mM Tris-HCL, pH 7.4) for 30 minutes at room temperature. Antagonist binding activity ismeasured, for example, by fluorescence polarization on a Perkin-Elmer LS50B luminescence spectrophotometer. Kd values are determined by nonlinear regression analysis using Graphpad prism software.
[00113] Any class of molecule, such as small organic molecules, peptides, oligonucleotides or proteins can be examined as putative antagonists in this assay. Acceptor proteins for BH3-peptides such as BCL2, BCL- XL, BAX or MCLl can be used in this assay. Acceptor proteins for p53 peptides such as MDM2 or MDMX can be used in this assay.
Binding Assays in Intact Cells.
[00114] It is possible to measure binding of peptides or peptidomimetic macrocycles to their natural acceptors in intact cells by immunoprecipitation experiments. For example, intact cells are incubated with fluoresceinated (FITC-labeled) compounds for 4 hrs in the absence of serum, followed by serum replacement and further incubation that ranges from 4-18 hrs. Cells are then pelleted and incubated in lysis buffer (5OmM Tris [pH 7.6], 150 mM NaCl, 1% CHAPS and protease inhibitor cocktail) for 10 minutes at
4°C. Extracts are centrifuged at 14,000 rpm for 15 minutes and supernatants collected and incubated with 10 μl goat anti-FITC antibody for 2 hrs, rotating at 4°C followed by further 2 hrs incubation at 4°C with protein A/G Sepharose (50 μl of 50% bead slurry). After quick centrifugation, the pellets are washed in lysis buffer containing increasing salt concentration (e.g., 150, 300, 500 mM). The beads are then re- equilibrated at 150 mM NaCl before addition of SDS-containing sample buffer and boiling. After centrifugation, the supernatants are optionally electrophoresed using 4%-12% gradient Bis-Tris gels followed by transfer into Immobilon-P membranes. After blocking, blots are optionally incubated with an antibody that detects FITC and also with one or more antibodies that detect proteins that bind to the peptidomimetic macrocycle, including BCL2, MCLl, BCL-XL, Al, BAX, BAK, MDM2 or MDMX.
Cellular Permeability Assays.
[00115] A peptidomimetic macrocycle is, for example, more cell permeable compared to a corresponding non- macrocyclic polypeptide. In some embodiments, the peptidomimetic macrocycles are more cell permeable than a corresponding non-macrocyclic polypeptides. Peptidomimetic macrocycles with optimized linkers possess, for example, cell permeability that is at least two-fold greater than a corresponding non- macrocyclic polypeptide, and often 20% or more of the applied peptide will be observed to have penetrated the cell after 4 hours.To measure the cell permeability of peptidomimetic macrocycles and corresponding non-macrocyclic polypeptides, intact cells are incubated with fluoresceinated peptidomimetic macrocycles or corresponding non-macrocyclic polypeptides (10 μM) for 4 hrs in serum free media at 37°C, washed twice with media and incubated with trypsin (0.25%) for 10 min at 37°C. The cells are washed again and resuspended in PBS. Cellular fluorescence is analyzed, for example, by using either a FACSCalibur flow cytometer or Cellomics' KineticScan ® HCS Reader.
Cellular Efficacy Assays. [00116] The efficacy of certain peptidomimetic macrocycles is determined, for example, in cell-based killing assays using a variety of tumorigenic and non-tumorigenic cell lines and primary cells derived from human or mouse cell populations. Cell viability is monitored, for example, over 24-96 hrs of incubation with . . assays that measure cell viability are commercially available and are optionally used to assess the efficacy of the peptidomimetic macrocycles. In addition, assays that measure Annexin V and caspase activation are optionally used to assess whether the peptidomimetic macrocycles kill cells by activating the apoptotic machinery.
In Vivo Stability Assay. [00117] To investigate the in vivo stability of the peptidomimetic macrocycles, the compounds are, for example,administered to mice and/or rat by IV, IP, PO or inhalation routes at concentrations ranging from 0.1 to 50 mg/Kg and blood specimens withdrawn at 0', 5', 15', 30', 1 hr, 4 hrs, 8 hrs and 24 hours post- injection. Levels of intact compound in 25 μL of fresh serum are then measured by LC-MS/MS as above.
In vivo Efficacy in Animal Models.
[00118] To determine the anti-oncogenic activity of the certain peptidomimetic macrocycles in vivo, the compounds are, for example, given alone (IP, IV, PO, by inhalation or nasal routes) or in combination with sub-optimal doses of relevant chemotherapy (e.g., cyclophosphamide, doxorubicin, etoposide). In one example, 5 x 106 RS4; 11 cells (established from the bone marrow of a patient with acute lymphoblastic leukemia) that stably express luciferase are injected by tail vein in NOD-SCID mice 3 hrs after they have been subjected to total body irradiation. If left untreated, this form of leukemia is fatal in 3 weeks in this model. The leukemia is readily monitored, for example, by injecting the mice with D-luciferin (60 mg/kg) and imaging the anesthetized animals (e.g., Xenogen In Vivo Imaging System, Caliper Life Sciences, Hopkinton, MA). Total body bioluminescence is quantified by integration of photonic flux (photons/sec) by Living Image
Software (Caliper Life Sciences, Hopkinton, MA). Peptidomimetic macrocycles alone or in combination with sub-optimal doses of relevant chemotherapeutics agents are, for example, administered to leukemic mice (10 days after injection/day 1 of experiment, in bioluminescence of 14-16) by tail vein or IP routes at doses ranging from 0.1 mg/kg to 50 mg/kg for 7 to 21 days. Optionally, the mice are imaged throughout the experiment every other day and survival monitored daily for the duration of the experiment. Expired mice are optionally subjected to necropsy at the end of the experiment. Another animal model is implantation of DoHH2, a cell line derived from human follicular lymphoma, into NOD-SCID mice that stably expresses luciferase. These in vivo tests optionally generate preliminary pharmacokinetic, pharmacodynamic and toxicology data.
Clinical Trials.
[00119] To determine the suitability of the peptidomimetic macrocycles of the invention for treatment of humans, clinical trials are performed. For example, patients diagnosed with cancer and in need of treatment are selected and separated in treatment and one or more control groups, wherein the treatment group is administered a peptidomimetic macrocycle of the invention, while the control groups receive a placebo or a known anti-cancer drug. The treatment safety and efficacy of the peptidomimetic macrocycles of the invention can thus be evaluated by performing comparisons of the patient groups with respect to factors such as survival and quality-of-life. In this example, the patient group treated with a peptidomimetic macrocyle show improved long-term survival compared to a patient control group treated with a placebo. [00120] The peptidomimetic macrocycles of the invention also include pharmaceutically acceptable derivatives or prodrugs thereof A "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, ester, salt of an ester, pro-drug or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention
Particularly favored pharmaceutically acceptable derivatives are those that increase the bioavailability of the compounds of the invention when administered to a mammal (e g , by increasing absorption into the blood of an orally administered compound) or which increases delivery of the active compound to a biological compartment (e g , the bram or lymphatic system) relative to the parent species Some pharmaceutically acceptable derivatives include a chemical group which increases aqueous solubility or active transport across the gastrointestinal mucosa
[00121] In some embodiments, the peptidomimetic macrocycles of the invention are modified by covalently or non- covalently joining appropπate functional groups to enhance selective biological properties Such modifications include those which increase biological penetration into a given biological compartment (e g , blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism, and alter rate of excretion [00122] Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable morganic and organic acids and bases Examples of suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, mcotinate, nitrate, palmoate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate and undecanoate Salts derived from appropriate bases include alkali metal (e g , sodium), alkaline earth metal [e g , magnesium), ammonium and N-(alkyl)4 + salts [00123] For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers include either solid or liquid carriers Solid form preparations include powders, tablets, pills, capsules, cachets, suppositones, and dispersible granules A solid carrier can be one or more substances, which also acts as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material Details on techniques for formulation and administration are well described in the scientific and patent literature, see, e g , the latest edition of Remington's Pharmaceutical Sciences,
Maack Publishing Co, Easton PA
[00124] In powders, the earner is a finely divided solid, which is in a mixture with the finely divided active component In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired [00125] Suitable solid excrpients are carbohydrate or protein fillers include, but are not limited to sugars, including lactose, sucrose, mannitol, or sorbitol, starch from corn, wheat, rice, potato, or other plants, cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose, and gums including arable and tragacanth, as well as proteins such as gelatin and collagen If desired, disintegrating or solubihzmg agents are added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate iqui orm prepara ions inc u e so u ions, suspensions, an emu sions, or examp e, wa er or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
[00127] The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. [00128] When the compositions of this invention comprise a combination of a peptidomimetic macrocycle and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. In some embodiments, the additional agents are administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents arepart of a single dosage form, mixed together with the compounds of this invention in a single composition.
Methods of use [00129] In one aspect, the present invention provides novel peptidomimetic macrocycles that are useful in competitive binding assays to identify agents which bind to the natural ligand(s) of the proteins or peptides upon which the peptidomimetic macrocycles are modeled. For example, in the p53 MDM2 system, labeled stabilized peptidomimetic macrocyles based on the p53 is used in an MDM2 binding assay along with small molecules that competitively bind to MDM2. Competitive binding studies allow for rapid in vitro evaluation and determination of drug candidates specific for the p53/MDM2 system. Likewise in the BH3/BCL-XL anti-apoptotic system labeled peptidomimetic macrocycles based on BH3 can be used in a BCL-XL binding assay along with small molecules that competitively bind to BCL-XL. Competitive binding studies allow for rapid in vitro evaluation and determination of drug candidates specific for the
BH3/BCL-XL system. The invention further provides for the generation of antibodies against the peptidomimetic macrocycles. In some embodiments, these antibodies specifically bind both the peptidomimetic macrocycle and the p53 or BH3 precursor peptides upon which the peptidomimetic macrocycles are derived. Such antibodies, for example, disrupt the ρ53/MDM2 or BH3/BCL-XL systems, respectively.
[00130] In other aspects, the present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant {e.g., insufficient or excessive) BCL-2 family member expression or activity {e.g., extrinsic or intrinsic apoptotic pathway abnormalities). It is believed that some BCL-2 type disorders are caused, at least in part, by an abnormal level of one or more BCL-2 family members {e.g., over or under expression), or by the presence of one or more BCL-2 family members exhibiting abnormal activity. As such, the reduction in the level and/or activity of the BCL-2 family member or the enhancement of the level and/or activity of the BCL-2 family member, is used, for example, to ameliorate or reduce the adverse symptoms of the disorder. [00131] In another aspect, the present invention provides methods for treating or preventing hyperproliferative disease by interfering with the interaction or binding between p53 and MDM2 in tumor cells. These methods comprise administering an effective amount of a compound of the invention to a warm blooded anima , inc u ing a uman, or o umor ce s con a n ng w ype p . n some em o imen s, e administration of the compounds of the present invention induce cell growth arrest or apoptosis. In other or further embodiments, the present invention is used to treat disease and/or tumor cells comprising elevated MDM2 levels. Elevated levels of MDM2 as used herein refers to MDM2 levels greater than those found in cells containing more than the normal copy number (2) of mdm2 or above about 10,000 molecules of
MDM2 per cell as measured by ELISA and similar assays (Picksley et al. (1994), Oncogene 9, 2523 2529). [00132] As used herein, the term "treatment" is defined as the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disease, a symptom of disease or a predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease, the symptoms of disease or the predisposition toward disease.
[00133] In some embodiments, he peptidomimetics macrocycles of the invention is used to treat, prevent, and/or diagnose cancers and neoplastic conditions. As used herein, the terms "cancer", "hyperproliferative" and "neoplastic" refer to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth. Hyperproliferative and neoplastic disease states may be categorized as pathologic, i.e., characterizing or constituting a disease state, or may be categorized as non- pathologic, i.e., a deviation from normal but not associated with a disease state. The term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. A metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of breast, lung, liver, colon and ovarian origin. "Pathologic hyperproliferative" cells occur in disease states characterized by malignant tumor growth. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair. Examples of cellular proliferative and/or differentiative disorders include cancer, e.g., carcinoma, sarcoma, or metastatic disorders. In some embodiments, the peptidomimetics macrocycles are novel therapeutic agents for controlling breast cancer, ovarian cancer, colon cancer, lung cancer, metastasis of such cancers and the like.
[00134] Examples of cancers or neoplastic conditions include, but are not limited to, a fibrosarcoma, myosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, gastric cancer, esophageal cancer, rectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, uterine cancer, cancer of the head and neck, skin cancer, brain cancer, squamous cell carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular cancer, small cell lung carcinoma, non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, lymphoma, or Kaposi sarcoma. [00135] Examples of proliferative disorders include hematopoietic neoplastic disorders. As used herein, the term "hematopoietic neoplastic disorders" includes diseases involving hyperplastic/neoplastic cells of hematopoietic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof. Preferably, the diseases arise from poorly differentiated acute leukemias, e.g., erythroblastic leukemia and acu e mega aryo as ic eu emia i iona exemp ary mye oi isor ers inc u e, u are no imi e o, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus (1991), Cnt Rev Oncol /Hemotol 11 267-97); lymphoid malignancies include, but are not limited to acute lymphoblastic leukemia (ALL) which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM) Additional forms of malignant lymphomas include, but are not limited to non-Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF), Hodgkm's disease and Reed-Stemberg disease [00136] Examples of cellular proliferative and/or differentiative disorders of the breast include, but are not limited to, proliferative breast disease including, e g , epithelial hyperplasia, sclerosing adenosis, and small duct papillomas, rumors, e g , stromal tumors such as fibroadenoma, phyllodes tumor, and sarcomas, and epithelial tumors such as large duct papilloma; carcinoma of the breast including in situ (noninvasive) carcinoma that includes ductal carcinoma in situ (including Paget's disease) and lobular carcinoma in situ, and invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, invasive lobular carcinoma, medullary carcinoma, colloid (mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma, and miscellaneous malignant neoplasms Disorders in the male breast include, but are not limited to, gynecomastia and carcinoma. [00137] Examples of cellular proliferative and/or differentiative disorders of the lung include, but are not limited to, bronchogenic carcinoma, including paraneoplastic syndromes, bronchioloalveolar carcinoma, neuroendocrine tumors, such as bronchial carcmoid, miscellaneous tumors, and metastatic tumors, pathologies of the pleura, including inflammatory pleural effusions, nonmflammatory pleural effusions, pneumothorax, and pleural tumors, including solitary fibrous tumors (pleural fibroma) and malignant mesothelioma [00138] Examples of cellular proliferative and/or differentiative disorders of the colon include, but are not limited to, non-neoplastic polyps, adenomas, familial syndromes, colorectal carcinogenesis, colorectal carcinoma, and carcmoid tumors
[00139] Examples of cellular proliferative and/or differentiative disorders of the liver include, but are not limited to, nodular hyperplasias, adenomas, and malignant tumors, including primary carcinoma of the liver and metastatic tumors.
[00140] Examples of cellular proliferative and/or differentiative disorders of the ovary include, but are not limited to, ovarian tumors such as, tumors of coelomic epithelium, serous tumors, mucinous tumors, endometrioid tumors, clear cell adenocarcinoma, cystadenofϊbroma, Brenner tumor, surface epithelial tumors, germ cell tumors such as mature (benign) teratomas, monodermal teratomas, immature malignant teratomas, dysgermmoma, endodermal sinus tumor, choriocarcinoma, sex cord-stomal tumors such as, granulosa- theca cell tumors, thecomafibromas, androblastomas, hill cell tumors, and gonadoblastoma, and metastatic tumors such as Krukenberg tumors [00141] In other or further embodiments, the peptidomimetics macrocycles described herein are used to treat, prevent or diagnose conditions characterized by overactive cell death or cellular death due to physiologic insult, etc Some examples of conditions characteπzed by premature or unwanted cell death are or alternatively unwanted or excessive cellular proliferation include, but are not limited to hypocellular/hypoplastic, acellular/aplastic, or hypercellular/hyperplastic conditions Some examples , , , congenital neutropenia, myelodysplasia [00142] In other or further embodiments, the peptidomimetics macrocycles of the invention that act to decrease apoptosis are used to treat disorders associated with an undesirable level of cell death. Thus, in some embodiments, the anti-apoptotic peptidomimetics macrocycles of the invention are used to treat disorders such as those that lead to cell death associated with viral infection, e.g. , infection associated with infection with human immunodeficiency virus (HIV). A wide variety of neurological diseases are characterized by the gradual loss of specific sets of neurons, and the anti-apoptotic peptidomimetics macrocycles of the invention are used, in some embodiments, in the treatment of these disorders. Such disorders include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) retinitis pigmentosa, spinal muscular atrophy, and various forms of cerebellar degeneration. The cell loss in these diseases does not induce an inflammatory response, and apoptosis appears to be the mechanism of cell death. In addition, a number of hematologic diseases are associated with a decreased production of blood cells. These disorders include anemia associated with chronic disease, aplastic anemia, chronic neutropenia, and the myelodysplastic syndromes. Disorders of blood cell production, such as myelodysplastic syndrome and some forms of aplastic anemia, are associated with increased apoptotic cell death within the bone marrow. These disorders could result from the activation of genes that promote apoptosis, acquired deficiencies in stromal cells or hematopoietic survival factors, or the direct effects of toxins and mediators of immune responses. Two common disorders associated with cell death are myocardial infarctions and stroke. In both disorders, cells within the central area of ischemia, which is produced in the event of acute loss of blood flow, appear to die rapidly as a result of necrosis. However, outside the central ischemic zone, cells die over a more protracted time period and morphologically appear to die by apoptosis. In other or further embodiments, the anti-apoptotic peptidomimetics macrocycles of the invention are used to treat all such disorders associated with undesirable cell death. [00143] Some examples of immunologic disorders that aretreated with the peptidomimetics macrocycles described herein include but are not limited to organ transplant rejection, arthritis, lupus, IBD, Crohn's disease, asthma, multiple sclerosis, diabetes, etc.
[00144] Some examples of neurologic disorders that are treated with the peptidomimetics macrocycles described herein include but are not limited to Alzheimer's Disease, Down's Syndrome, Dutch Type Hereditary Cerebral Hemorrhage Amyloidosis, Reactive Amyloidosis, Familial Amyloid Nephropathy with Urticaria and Deafness, Muckle-Wells Syndrome, Idiopathic Myeloma; Macroglobulinemia-Associated Myeloma, Familial Amyloid Polyneuropathy, Familial Amyloid Cardiomyopathy, Isolated Cardiac Amyloid, Systemic Senile Amyloidosis, Adult Onset Diabetes, Insulinoma, Isolated Atrial Amyloid, Medullary Carcinoma of the Thyroid, Familial Amyloidosis, Hereditary Cerebral Hemorrhage With Amyloidosis, Familial Amyloidotic Polyneuropathy, Scrapie, Creutzfeldt-Jacob Disease, Gerstmann Straussler-Scheinker
Syndrome, Bovine Spongiform Encephalitis, a prion-mediated disease, and Huntington's Disease. [00145] Some examples of endocrinologic disorders that are treated with the peptidomimetics macrocycles described herein include but are not limited to diabetes, hypothyroidism, hypopituitarism, hypoparathyroidism, hypogonadism, etc. [00146] Examples of cardiovascular disorders (e.g., inflammatory disorders) that are treated or prevented with the peptidomimetics macrocycles of the invention include, but are not limited to, atherosclerosis, myocardial infarction, stroke, thrombosis, aneurism, heart failure, ischemic heart disease, angina pectoris, sudden . . car iac ea , yper ensive ear isease, non-coronary vesse isease, suc as ar eπo osc erosis, sma vessel disease, nephropathy, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, xanthomatosis, asthma, hypertension, emphysema and chronic pulmonary disease, or a cardiovascular condition associated with interventional procedures ("procedural vascular trauma"), such as restenosis following angioplasty, placement of a shunt, stent, synthetic or natural excision grafts, indwelling catheter, valve or other implantable devices Preferred cardiovascular disorders include atherosclerosis, myocardial infarction, aneurism, and stroke.
Examples [00147] The following section provides illustrative examples of the present invention
[00148] Example 1 Synthesis of a peptidomimetic macrocycle The target molecule is the BID-BH3 peptide with amino acids 12 and 16 replaced by Cysteine (see Table 1 and Table 6). The Cysteine side chain thiols are then denvatized with 1,4-dibromobutane to form the bis-thioether peptidomimetic macrocycle
Ac -DIIRNIARHLA- HN NH2
Figure imgf000043_0001
[00149] Following the general peptide synthetic strategy described, the peptidomimetic precursor was a polypeptide of the sequence DIIARHLACVGDCNLDRSI (where "NL" or "NIe" represent norleucme) synthesized at
0 2 mmol scale on a PTI-Ranin PS3 single channel synthesizer using the following coupling cycles for each amino acid
Deprotection 20% pipeπdine in DMF 2 x 7 nun
Wash DMF 6 x 0 5 mm
Coupling 5 fold excess each of amino acid, TBTU and DIEA in DMF 1 x 20 mm
Wash DMF 2 x 0.5 mm Coupling 5 fold excess each of amino acid, TBTU and DIEA in DMF 1 x 20 mm
Wash DMF 6 x 0.5 mm
[00150] The precursor polypeptide was acetylated at the amino terminus by treatment with ImM acetic anhydride and ImM dnsopropylethylamine (DIEA) in dimethylformamide (DMF) for 45 minutes Synthesis was done on rink amide resin (substitution 0 6mMol/g) with the cys9 and cys13 thiols protected with p-methoxytπtyl
(Mmt) groups The Mmt groups were selectively deprotected with 1% TF A/4% TIS in dichloromethane (DCM) and the polypeptide was alkylated overnight at room temperature using 50 molar equivalents of 1 ,4-dibromobutane and 13 molar equivalents of dnsopropylethylamine (DIEA) in dichloroethane The peptide was then cleaved from the resin by treatment with 94% TFA 2% TIS 2% Anisole 2% H2O for 3 hours followed by filtration, concentration by rotary evaporation and precipitation with diethyl ether The expected molecular weight of the final peptidomimetic macrocycle product is 2448 91 The observed molecular weight is 2445 5 by MALDI MS (see Figure 1) . , various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

Claims

WHAT IS CLAIMED IS:
1. A peptidomimetic macrocycle of Formula (I):
Figure imgf000045_0001
wherein: each A, C, D, and E is independently a natural or non-natural amino acid;
B is a natural or non-natural amino acid, amino acid
Figure imgf000045_0002
[-NH-L4-CO-],
[-NH-L4-SO2-], or [-NH-L4-]; R1 and R2 are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-;
R3 is hydrogen, alkyl, alkenyl, alkynyl, arylalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R5;
Li, L2, L3 and L4 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [-R4-K-R4-Jn, each being unsubstituted or substituted with R5;
K is O, S, SO, SO2, CO, CO2, or CONR3; each R4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each R5 is independently halogen, alkyl, -OR6, -N(Re)2, -SR6, -SOR6, -SO2R6, -CO2R6, a fluorescent moiety, a radioisotope or a therapeutic agent; each R6 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
R7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R5j or part of a cyclic structure with a D residue;
R8 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, cycloaryl, or heterocycloaryl, unsubstituted or substituted with R5j or part of a cyclic structure with an E residue; v is an integer from 1-1000; w is an integer from 1-1000; x is an integer from 0-10; y is an integer from 0-10; z is an integer from 0-10; n is an integer from 1 -5 ; and x+y+z is at least 3.
. , i 2 , , , arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo™.
3. The peptidomimetic macrocycle of claim 1, wherein Rt and R2 are independently alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-. 4. The peptidomimetic macrocycle of claim 1, wherein at least one of K1 and R2 is alkyl, unsubstituted or substituted with halo-.
5. The peptidomimetic macrocycle of claim 1, wherein Ri and R2 are independently alkyl, unsubstituted or substituted with halo-.
6. The peptidomimetic macrocycle of claim 1, wherein at least one OfR1 and R2 is methyl. 7. The peptidomimetic macrocycle of claim 1, wherein Ri and R2 are methyl.
8. The peptidomimetic macrocycle of claim 1, wherein at least one of D and E is a natural or unnatural ammo acid substituted with a high molecular weight lipid or hydrocarbon
9. The peptidomimetic macrocycle of claim 1, wherein at least one of D and E is attached to an additional macrocycle-forming linker of the formula [-Li-S-L2-S-L3-]. 10. The peptidomimetic macrocycle of claim 1 wherein wherein a secondary structure of the peptidomimetic macrocycle is more stable than a corresponding secondary structure of a corresponding non-macrocychc polypeptide.
11. The peptidomimetic macrocycle of claim 1 wherein the peptidomimetic macrocycle comprises an α-helix. 12 The peptidomimetic macrocycle of claim 11 wherein the α-helix comprises from 1 turn to 5 turns 13. The peptidomimetic macrocycle of claim 11 wherein the α-hehx is more stable than an α-helix of a corresponding non-macrocyclic polypeptide.
14. The peptidomimetic macrocycle of claim 11 wherein [-Lj-S-L2-S-L3-] spans from 1 turn to 5 turns of the α- hehx.
15. The peptidomimetic macrocycle of claim 11 wherein [-Li-S-L2-S-L3-] spans approximately 1, 2, 3, 4 or 5 turns of the α-helix.
16. The peptidomimetic macrocycle of claim 11 wherein the length of [-Li-S-L2-S-L3-] is about 5 A to about 9 A per turn of the α-hehx
17. The peptidomimetic macrocycle of claim 11 wherein [-Li-S-L2-S-L3-] spans approximately 1 turn of the α- helix. 18. The peptidomimetic macrocycle of claim 17 wherein the length of [-Li-S-L2-S-L3-] is approximately equal to the length of from about 5 carbon-carbon bonds to about 13 carbon-carbon bonds.
19. The peptidomimetic macrocycle of claim 17 wherein the length of [-L1-S-L2-S-L3-] is approximately equal to the length of from about 7 carbon-carbon bonds to about 10 carbon-carbon bonds.
20. The peptidomimetic macrocycle of claim 17 wherein the macrocycle comprises a ring of about 17 atoms to 25 atoms.
21 The peptidomimetic macrocycle of claim 11 wherein the α-hehx comprises about 2 turns.
22. The peptidomimetic macrocycle of claim 21 wherein the length of [-L1-S-L2-S-L3-] is approximately equal to the length of from about 8 carbon-carbon bonds to about 16 carbon-carbon bonds.
23. The peptidomimetic macrocycle of claim 21 wherein the length of [-Li-S-L2-S-L3-] is approximately equal to the length of from about 10 carbon-carbon bonds to about 13 carbon-carbon bonds.
24. The peptidomimetic macrocycle of claim 21 wherein the macrocycle comprises a ring of about 29 atoms to about 37 atoms.
. compoun o ormu a a:
PQ
Figure imgf000047_0001
R9 (Formula Ha) wherein:
R1 is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl; Li is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene or [-R4-K-R4-Jn, unsubstituted or substituted with R5;
K is O, S, SO, SO2, CO, CO2, or CONR3;
R4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; R5 is independently halogen, alkyl, -OR6, -N(Re)2, -SR6, -SOR6, -SO2R6, -CO2R6, a fluorescent moiety, a radioisotope or a therapeutic agent;
R6 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
R7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, or heterocyclyalkyl; R9 and R10 are independently -H or a protecting group suitable for peptide synthesis; n is an integer from 1 to 5;
Q is S; and
P is -H, -trityl, /7-methoxytrityl, -S f-butyl, or any other protecting group suitable for peptide synthesis; or Q and P when taken together form a moiety capable of undergoing chemical transformation into an -SH group. 26. The compound of claim 25, wherein Ri is alkyl, unsubstituted or substituted with halo-.
27. The compound of claim 25, wherein R1 is unsubstituted alkyl.
28. The compound of claim 25, wherein R1 is methyl.
29. The compound of claim 25, wherein at least one of R9 and Ri0 is a protected group suitable for peptide synthesis. 30. A kit comprising a) a compound of Formulas IIa and a compound of Formula lib:
Figure imgf000047_0002
Ha lib
wherein
. 1 is a y , a eny , a yny , ary a y , cyc oa y , e eroa y , or e erocyc oa y , unsu s i u e or su s u e wi halo-;
R2 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo—; Li and L3 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, or heterocycloarylene or [-R4-K-R4-Jn, each being unsubstituted or substituted with R5;
K is O, S, SO, SO2, CO, CO2, or CONR3;
R4 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each R5 is independently halogen, alkyl, -OR6, -N(R6J2, -SR6, -SOR6, -SO2R6, -CO2R6, -R6, a fluorescent moiety, a radioisotope, or a therapeutic agent; each R6 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent;
R7 and R8 are independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, or heterocyclyalkyl;
R9 and Ri0 are each independently -H or any protecting group suitable for liquid or solid phase peptide synthesis;
Q is S;
P is — H, -trityl, /j-methoxytrityl, -S /-butyl, or any other protecting group suitable for liquid or solid phase peptide synthesis; or Q and P when taken together form a moiety capable of undergoing chemical transformation into an -SH group; n is an integer from 1 to 5; and b) a macrocycle-forming linker of the structure:
X-L2-Y wherein L2 is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, cycloarylene, heterocycloarylene, or [-Ri rK-Ri t-]n, each being unsubstituted or substituted with R12; each Rn is alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene; each R12 is independently halogen, alkyl, -OR13, -N(R6)I3, -SR13, -SOR]3, -SO2R13, -CO2Rj3, -R13, a fluorescent moiety, a radioisotope, or a therapeutic agent; each R13 is independently -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroalkylalkyl, heterocyclyalkyl, a fluorescent moiety, a radioisotope, or a therapeutic agent; and
X and Y are each independently a reactive group capable of reacting with a thiol group.
31. The kit of claim 30, wherein R2 is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo. 32. The kit of claim 30, wherein R1 and R2 are alkyl.
33. The kit of claim 30, wherein R1 and R2 are methyl.
34. A method for synthesizing a peptidomimetic macrocycle, the method comprising the step of contacting a peptidomimetic precursor of the Formula III:
Figure imgf000048_0001
wi c mp u ormu a - 2- , wherein v, w, x, y, z, A, B, C, D, E, Rb R2, R7, R8, L1, L2, and L3 are as defined in claim 1 , and X and Y are each independently a reactive group capable of reacting with a thiol group; x+y+z is at least 3, and further wherein said contacting step results in a covalent linkage being formed between the two thiol groups m Formula III.
35 The method of claim 34, wherein at least one of Ri and R2 is alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo—
36 The method of claim 34, wherein Rj and R2 are independently alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo—
37 The method of claim 34, wherein at least one OfR1 and R2 is alkyl, unsubstituted or substituted with halo- 38. The method of claim 34, wherem R1 and R2 are independently alkyl, unsubstituted or substituted with halo-.
39 The method of claim 34, wherein at least one OfR1 and R2 is methyl
40 The method of claim 34, wherem Ri and R2 are methyl 41 The method of claim 34, wherem the peptidomimetic precursor is expressed in cells
42 The method of claim 34, wherem the peptidomimetic precursor is purified prior to the contacting step
43 The method of claim 34, wherem the peptidomimetic macrocycle is purified after the contacting step
44 The method of claim 34, wherem the peptidomimetic macrocycle is refolded after the contacting step
45 The method of claim 34, wherem the method is performed in solution 46 The method of claim 34, wherem the method is performed on a solid support
47 The method of claim 34, wherem the contacting step is performed in the presence of a target macromolecule that binds to the peptidomimetic precursor under conditions that favor said binding.
48 The method of claim 34, wherem the contacting step is performed in the presence of a target macromolecule that binds preferentially to the peptidomimetic precursor under conditions that favor said binding 49. The method of claim 34, wherem the method is applied to synthesize a library of peptidomimetic macrocycles.
50 The method of claim 34, wherein the peptidomimetic macrocycle compπses an α-hehx in aqueous solution
51 The method of claim 34, wherein the peptidomimetic macrocycle exhibits mcreased α-hehcal structure in aqueous solution compared to a corresponding non-macrocychc polypeptide.
52 The method of claim 34, wherem the peptidomimetic macrocycle exhibits increased thermal stability compared to a corresponding non-macrocychc polypeptide
53 The method of claim 34, wherem the peptidomimetic macrocycle exhibits mcreased biological activity compared to a corresponding non-macrocyclic polypeptide
54 The method of claim 34, wherein the peptidomimetic macrocycle exhibits increased resistance to proteolytic degradation compared to a corresponding non-macrocychc polypeptide 55 The method of claim 34, wherein the peptidomimetic macrocycle exhibits mcreased ability to penetrate living cells compared to a corresponding non-macrocychc polypeptide 56 The method of claim 34, wherem the two thiol moieties of the compound of Formula III are sidechains of an amino acid selected from the group consisting of L-cysteine, D-cysteme, α-methyl L-cysteine, and α-methyl D- cysteine 57 The method of claim 34, wherein x+y+z is 3, and A, B and C are independently natural or non-natural amino acids
. . e meno o caim , w erein e conacing sep is perorme in a soven seece rom e group consisting of protic solvent, aqueous solvent, organic solvent, and mixtures thereof.
59. The method of claim 34, wherein the solvent is DMF, dichloroethane, NH3, NH3/MeOH, NH3/DMF, or aqueous guanidinium-H CL .
60. The method of claim 34, wherein the solvent is a solvent that favors helix formation.
61. The method of claim 34, wherein the peptidomimetic macrocycle has the Formula (I):
Figure imgf000050_0001
(Formula I)
PCT/US2007/087615 2006-12-14 2007-12-14 Bis-sulfhydryl macrocyclization systems WO2008076904A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2007333846A AU2007333846B2 (en) 2006-12-14 2007-12-14 Bis-sulfhydryl macrocyclization systems
CA2686827A CA2686827C (en) 2006-12-14 2007-12-14 Bis-sulfhydryl macrocyclization systems
CN200780050407.3A CN101636407B (en) 2006-12-14 2007-12-14 Bis-sulfhydryl macrocyclization systems
JP2009541617A JP5656407B2 (en) 2006-12-14 2007-12-14 Bis-sulfhydryl macrocyclic system
EP07869296.9A EP2094721B1 (en) 2006-12-14 2007-12-14 Bis-sulfhydryl macrocyclization systems
BRPI0720306-3A BRPI0720306A2 (en) 2006-12-14 2007-12-14 BIS-SUFIDRIL MACROCYCLING SYSTEMS
HK10104096.3A HK1137184B (en) 2006-12-14 2007-12-14 Bis-sulfhydryl macrocyclization systems
IL199301A IL199301A (en) 2006-12-14 2009-06-11 Bis-sulfhydryl macrocyclization systems

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87481906P 2006-12-14 2006-12-14
US60/874,819 2006-12-14

Publications (2)

Publication Number Publication Date
WO2008076904A1 true WO2008076904A1 (en) 2008-06-26
WO2008076904A9 WO2008076904A9 (en) 2017-04-27

Family

ID=39536693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/087615 WO2008076904A1 (en) 2006-12-14 2007-12-14 Bis-sulfhydryl macrocyclization systems

Country Status (9)

Country Link
US (5) US7960506B2 (en)
EP (2) EP3170835A1 (en)
JP (3) JP5656407B2 (en)
CN (2) CN105061577A (en)
AU (1) AU2007333846B2 (en)
BR (1) BRPI0720306A2 (en)
CA (1) CA2686827C (en)
IL (1) IL199301A (en)
WO (1) WO2008076904A1 (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010034031A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010034029A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010034034A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010034028A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic marcrocycles
WO2010034026A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010099436A1 (en) * 2009-02-27 2010-09-02 Mimetogen Pharmaceuticals, Inc. Methods of treating retinitis pigmentosa
EP2285970A4 (en) * 2008-06-03 2011-10-12 Aileron Therapeutics Inc COMPOSITIONS AND METHODS FOR ENHANCING CELL TRANSPORT OF BIOMOLECULES
EP2334317A4 (en) * 2008-09-16 2012-03-14 Univ New York State Res Found AGRAFTED PEPTIDES AND METHOD OF SYNTHESIS
WO2013126703A1 (en) * 2012-02-22 2013-08-29 New York University Reversibly crosslinked helical hydrogen bond surrogate macrocycles
CN104159595A (en) * 2012-02-15 2014-11-19 爱勒让治疗公司 Peptidomimetic macrocycles
US9074009B2 (en) 2006-11-15 2015-07-07 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9175056B2 (en) 2006-12-14 2015-11-03 Alleron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US9458202B2 (en) 2008-11-24 2016-10-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
US9493509B2 (en) 2007-02-23 2016-11-15 Aileron Therapeutics, Inc. Triazole macrocycle systems
US9527896B2 (en) 2007-01-31 2016-12-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9957299B2 (en) 2010-08-13 2018-05-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
EP3310373A4 (en) * 2015-06-22 2019-02-13 University of Utah Research Foundation THIOL-EN-BASED PEPTIDE HOLDING AND USES THEREOF
US10227380B2 (en) 2012-02-15 2019-03-12 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10301351B2 (en) 2007-03-28 2019-05-28 President And Fellows Of Harvard College Stitched polypeptides
US10300109B2 (en) 2009-09-22 2019-05-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
US11034720B2 (en) 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
WO2025040657A1 (en) * 2023-08-21 2025-02-27 Medizinische Universität Wien Selective cyclized peptide kappa-opioid receptor antagonists

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
WO2005044839A2 (en) 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
JP5883220B2 (en) * 2007-05-02 2016-03-09 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Methods of modulating cellular homeostasis pathways and cell survival
US8871899B2 (en) * 2007-12-31 2014-10-28 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
BRPI0907754A2 (en) 2008-02-08 2015-07-21 Aileron Therapeutics Inc Therapeutic peptidomimetic macrocycles
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
EP2310407A4 (en) * 2008-04-08 2011-09-14 Aileron Therapeutics Inc BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES
US20110144306A1 (en) * 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
BRPI0918838A2 (en) 2008-09-22 2015-12-08 Aileron Therapeutics Inc processes for preparing purified polypeptide compositions
CA2768299C (en) 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
CA2777700A1 (en) * 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles
US8957026B2 (en) 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US10822374B2 (en) 2010-11-12 2020-11-03 Dana-Farber Cancer Institute, Inc. Cancer therapies and diagnostics
EP2651964B1 (en) 2010-12-15 2018-02-28 The Research Foundation of State University of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
EP2670418A4 (en) * 2011-02-04 2015-06-17 Aegis Therapeutics Llc Orally bioavailable peptide drug compositions and methods thereof
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
WO2013173755A1 (en) 2012-05-18 2013-11-21 The Regents Of The University Of California Modification of peptides using a bis(thioether)arylbridge approach
RS61957B1 (en) 2012-09-26 2021-07-30 Harvard College Proline-locked stapled peptides and uses thereof
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
KR102637496B1 (en) 2013-03-13 2024-02-19 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Stapled and stitched polypeptides and uses thereof
AU2014278005B2 (en) 2013-06-14 2018-11-22 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CN112321678A (en) * 2013-10-28 2021-02-05 诺雷克斯股份有限公司 NMDA receptor modulators and their prodrugs, salts and uses
JP6572497B2 (en) 2013-12-18 2019-09-11 ザ・スクリップス・リサーチ・インスティテュート Modified therapeutic agents, stapled peptide lipid complexes, and compositions thereof
EP3126375B1 (en) * 2014-04-02 2023-12-13 University of Rochester Macrocyclic peptidomimetics for alpha-helix mimicry
US10533039B2 (en) 2014-05-21 2020-01-14 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US11345725B2 (en) 2019-09-16 2022-05-31 Research Foundation Of The City University Of New York Bis-thioether stapled peptides as inhibitors of PRC2 function
WO2022257979A1 (en) 2021-06-09 2022-12-15 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030072A1 (en) 1996-02-20 1997-08-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin d and plasmepsins i and ii
WO1998046631A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Combinatorial libraries of peptidomimetic macrocycles and processes therefor
WO2005044839A2 (en) 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US20050119167A1 (en) * 2003-06-02 2005-06-02 Giovanni Abbenante Process for the preparation of cyclic peptides

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000259A (en) * 1975-06-16 1976-12-28 American Home Products Corporation Cyclic dodecapeptide analogs of somatostatin and intermediates
US4438270A (en) 1977-07-11 1984-03-20 Merrell Toraude Et Compagnie α-Halomethyl derivatives of α-amino acids
US4191754A (en) * 1979-02-28 1980-03-04 Merck & Co., Inc. Bicyclic somatostatin analogs
WO1989009233A1 (en) 1988-03-24 1989-10-05 Terrapin Technologies, Inc. Molecular sticks for controlling protein conformation
US5650133A (en) * 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
CA2047042A1 (en) * 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
CA2103577A1 (en) 1991-02-07 1992-08-08 Michael Kahn Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
AU662731B2 (en) 1991-04-09 1995-09-14 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
US5364851A (en) * 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
GB9114949D0 (en) 1991-07-11 1991-08-28 Smithkline Beecham Plc Novel compounds
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
WO1994025482A1 (en) 1993-04-23 1994-11-10 Evans Herbert J Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5622852A (en) * 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US5770377A (en) * 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5675001A (en) 1995-03-14 1997-10-07 Hoffman/Barrett, L.L.C. Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
ATE203248T1 (en) 1995-05-04 2001-08-15 Scripps Research Inst PROTEIN SYNTHESIS USING NATIVE CHEMICAL LIGATION (07.01.97)
US5811515A (en) * 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US5840833A (en) * 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5849954A (en) 1996-01-18 1998-12-15 Research Corporation Technologies, Inc. Method of peptide synthesis
US5817752A (en) * 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US5663316A (en) * 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US5955593A (en) * 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US5965703A (en) * 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5856445A (en) * 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US5955893A (en) * 1996-12-16 1999-09-21 Macronix International Co., Ltd. Power saving buffer circuit buffer bias voltages
EP0989136A4 (en) 1997-05-15 2002-10-09 Kyowa Hakko Kogyo Kk PEPTIDES WITH CYCLIC STRUCTURES AND A RESTORING EFFECT OF P53 PROTEIN ACTIVITY ON THE MUTANTS OF SAID PROTEIN
US7064193B1 (en) * 1997-09-17 2006-06-20 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
US6326354B1 (en) * 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
JP2003503008A (en) 1999-03-01 2003-01-28 バリアジェニックス インコーポレーテッド Methods for targeting RNA molecules
TR200102765T2 (en) * 1999-03-29 2002-05-21 The Procter & Gamble Company Melanocortin receptor ligands
US6713280B1 (en) * 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
DE10009341A1 (en) 2000-02-22 2001-09-06 Florian Kern Method for antigen-specific stimulation of T lymphocytes
US6703382B2 (en) * 2000-08-16 2004-03-09 Georgetown University Medical Center Small molecule inhibitors targeted at Bcl-2
AU2002252246A1 (en) 2001-03-09 2002-09-24 University Of Louisville Helicomimetics and stabilized lxxll peptidomimetics
US20040106548A1 (en) * 2001-09-07 2004-06-03 Schmidt Michelle A Conformationally constrained labeled peptides for imaging and therapy
CA2471719A1 (en) * 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
EP1468013A4 (en) 2002-01-03 2005-03-16 Yissum Res Dev Co Conformationally constrained c-backbone cyclic peptides
WO2003070892A2 (en) 2002-02-15 2003-08-28 The Regents Of The University Of Michigan Inhibitors of rgs proteins
US20030166138A1 (en) * 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
KR101138643B1 (en) * 2002-05-30 2012-04-26 더 스크립스 리서치 인스티튜트 Copper-catalysed ligation of azides and acetylenes
AU2003261774A1 (en) * 2002-09-06 2004-03-29 Kaneka Corporation PROCESS FOR PRODUCING L-Alpha-METHYLCYSTEINE DERIVATIVE
US20040171809A1 (en) * 2002-09-09 2004-09-02 Korsmeyer Stanley J. BH3 peptides and method of use thereof
AU2003277891A1 (en) 2002-09-23 2004-04-08 Medivir Ab Hcv ns-3 serine protease inhibitors
EP2135868A1 (en) * 2002-11-07 2009-12-23 Kosan Biosciences Incorporated Trans-9, 10-dehydroepothilone c and d, analogs thereof and methods of making the same
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
WO2005007675A2 (en) 2003-07-09 2005-01-27 The Scripps Research Institute TRIAZOLE &epsiv;-AMINO ACIDS
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
EP1673078B1 (en) 2003-10-03 2008-05-28 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EP1673386A2 (en) 2003-10-16 2006-06-28 AplaGen GmbH Stabilized alpha-helical peptides
US8193310B2 (en) 2004-03-19 2012-06-05 The University Of Queensland Alpha helical mimics, their uses and methods for their production
US7202332B2 (en) * 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
EP1602663A1 (en) 2004-06-04 2005-12-07 Chiralix B.V. Triazole-linked glycoamino acids and glycopeptides
CN100335467C (en) 2004-06-04 2007-09-05 中国科学院上海有机化学研究所 Synthesis of 5-iodo-1,4-twice substituted-1,2,3-trioxazole compound
CA2585373A1 (en) * 2004-10-29 2006-05-11 Schering Corporation Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
SI1844337T1 (en) 2005-01-24 2013-11-29 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
US20070020620A1 (en) 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
WO2008013454A2 (en) 2006-07-26 2008-01-31 Pepscan Systems B.V. Immunogenic compounds and protein mimics
US20080213175A1 (en) * 2006-09-15 2008-09-04 Kolb Hartmuth C Click chemistry-derived cyclic peptidomimetics as integrin markers
WO2008061192A2 (en) 2006-11-15 2008-05-22 Dana-Farber Cancer Institute, Inc. Stabilized maml peptides and uses thereof
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7960506B2 (en) 2006-12-14 2011-06-14 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
EP2121007A1 (en) 2006-12-21 2009-11-25 Cytos Biotechnology AG Circular ccr5 peptide conjugates and uses thereof
ES2558928T3 (en) 2007-01-31 2016-02-09 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
AU2008218116B2 (en) 2007-02-23 2012-04-05 Aileron Therapeutics, Inc. Triazole macrocycle systems
BRPI0809366B8 (en) 2007-03-28 2021-05-25 Harvard College substantially alpha-helical polypeptide, method for manufacturing same, amino acid and pharmaceutical composition
JP5883220B2 (en) * 2007-05-02 2016-03-09 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Methods of modulating cellular homeostasis pathways and cell survival
US8871899B2 (en) 2007-12-31 2014-10-28 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
JP6157046B2 (en) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド Method for generating antibody Fc heterodimer molecules using electrostatic steering effect
BRPI0907754A2 (en) 2008-02-08 2015-07-21 Aileron Therapeutics Inc Therapeutic peptidomimetic macrocycles
EP2310407A4 (en) 2008-04-08 2011-09-14 Aileron Therapeutics Inc BIOLOGIC EFFECTIVE PEPTIDOMIMETIC MACROCYCLES
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
WO2009149214A2 (en) 2008-06-03 2009-12-10 Aileron Therapeutics, Inc. Compositions and methods for enhancing cellular transport of biomolecules
US20110144306A1 (en) 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
CN102216322A (en) 2008-09-18 2011-10-12 纽约大学 Inhibition of the interaction between HIF-1α and p300/CBP with a helix based on hydrogen bond substitution
US20120101047A1 (en) 2008-09-22 2012-04-26 Aileron Therapetics Inc. Peptidomimetic macrocycles
US20120115793A1 (en) 2008-09-22 2012-05-10 Alleron therapeutics, Inc Peptidomimetic macrocycles
WO2010034028A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic marcrocycles
AU2009294877C1 (en) 2008-09-22 2015-05-07 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20120178700A1 (en) 2008-09-22 2012-07-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BRPI0918838A2 (en) 2008-09-22 2015-12-08 Aileron Therapeutics Inc processes for preparing purified polypeptide compositions
JP2012509902A (en) 2008-11-24 2012-04-26 エルロン・セラピューティクス・インコーポレイテッド Peptidomimetic macrocycles with improved properties
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2768299C (en) 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
EP2480565A4 (en) 2009-09-22 2014-01-01 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
CA2777700A1 (en) 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
CA2828889A1 (en) 2011-03-04 2012-09-13 New York University Hydrogen bond surrogate macrocycles as modulators of ras
WO2012173846A2 (en) 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN103889437A (en) 2011-08-31 2014-06-25 纽约大学 Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics
TWI643868B (en) 2011-10-18 2018-12-11 艾利倫治療公司 Peptidomimetic macrocycles
WO2013059530A2 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108912211A (en) 2012-02-15 2018-11-30 爱勒让治疗公司 Triazole crosslinking and thioether crosslinking peptidomimetic macrocyclic compound
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
US20170037086A1 (en) 2014-04-09 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with pth activity
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP2018503595A (en) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Peptidomimetic macrocycle and its preparation
KR20170129879A (en) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 Peptidomimetic macrocycles and their uses
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3317294B1 (en) 2015-07-02 2023-03-15 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
US20170037105A1 (en) 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017040990A1 (en) 2015-09-03 2017-03-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
JP2019520304A (en) 2016-03-21 2019-07-18 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Companion diagnostic tool for peptidomimetic macrocycles
WO2017205786A1 (en) 2016-05-27 2017-11-30 Aileron Therapeutics, Inc. Cell permeable peptidomimetic macrocycles
US20170360881A1 (en) 2016-06-17 2017-12-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030072A1 (en) 1996-02-20 1997-08-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin d and plasmepsins i and ii
WO1998046631A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Combinatorial libraries of peptidomimetic macrocycles and processes therefor
US20050119167A1 (en) * 2003-06-02 2005-06-02 Giovanni Abbenante Process for the preparation of cyclic peptides
WO2005044839A2 (en) 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"Encyclopedia of Reagents for Organic Synthesis", 1995, JOHN WILEY AND SONS
"Remington's Pharmaceutical Sciences", MAACK PUBLISHING CO
BARKER P.I. ET AL.: "Cyclid RGD peptide analogues as antiplatelet antibromboties", J. MED. CHEM., vol. 35, 1992, pages 2040 - 2048, XP000651682 *
BLACKWELL ET AL., ANGEW. CHEM. INT. ED., vol. 37, 1998, pages 3281 - 3284
BRUNEI ET AL., CHEM. COMMUN., 2005, pages 2552 - 2554
FIELDS ET AL.: "Synthetic Peptides: A User's Guide", 1992, W. H. FREEMAN & CO., pages: 77
FIESER; FIESER: "Fieser and Fieser's Reagents for Organic Synthesis", 1994, JOHN WILEY AND SONS
GREENE; WUTS: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY AND SONS
HANESSIAN ET AL., J.MED.CHEM., vol. 49, 2006, pages 4544 - 4567
HIROSHIGE ET AL., J. AM. CHEM. SOC., vol. 117, 1995, pages 11590 - 11591
JACKSON ET AL., J. AM. CHEM. SOC., vol. 113, 1991, pages 9391 - 9392
LAROCK: "Comprehensive Organic Transformations", 1989, CH PUBLISHERS
PHELAN ET AL., J. AM. CHEM. SOC., vol. 119, 1997, pages 455 - 460
PICKSLEY ET AL., ONCOGENE, vol. 9, 1994, pages 2523 2529
SCHAFMEISTER ET AL., J. AM. CHEM. SOC., vol. 122, 2000, pages 5891 - 5892
TAYLOR, BIOPOLYMERS, vol. 66, 2002, pages 49 - 75
WALKER ET AL., TETRAHEDRON LETTERS, vol. 42, 2001, pages 5801 - 5804

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074009B2 (en) 2006-11-15 2015-07-07 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
US10328117B2 (en) 2006-12-14 2019-06-25 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US9675661B2 (en) 2006-12-14 2017-06-13 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US9175056B2 (en) 2006-12-14 2015-11-03 Alleron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US9527896B2 (en) 2007-01-31 2016-12-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US10030049B2 (en) 2007-02-23 2018-07-24 Aileron Therapeutics, Inc. Triazole macrocycle systems
US9957296B2 (en) 2007-02-23 2018-05-01 Aileron Therapeutics, Inc. Triazole macrocycle systems
US9493509B2 (en) 2007-02-23 2016-11-15 Aileron Therapeutics, Inc. Triazole macrocycle systems
US10301351B2 (en) 2007-03-28 2019-05-28 President And Fellows Of Harvard College Stitched polypeptides
EP2285970A4 (en) * 2008-06-03 2011-10-12 Aileron Therapeutics Inc COMPOSITIONS AND METHODS FOR ENHANCING CELL TRANSPORT OF BIOMOLECULES
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
EP2334317A4 (en) * 2008-09-16 2012-03-14 Univ New York State Res Found AGRAFTED PEPTIDES AND METHOD OF SYNTHESIS
JP2016190882A (en) * 2008-09-22 2016-11-10 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Peptidomimetic macrocycles
US9175045B2 (en) 2008-09-22 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010034029A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8524653B2 (en) 2008-09-22 2013-09-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8399405B2 (en) 2008-09-22 2013-03-19 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010034028A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic marcrocycles
AU2009294877B2 (en) * 2008-09-22 2014-11-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2012503026A (en) * 2008-09-22 2012-02-02 エルロン・セラピューティクス・インコーポレイテッド Peptidomimetic macrocycle
JP2014221801A (en) * 2008-09-22 2014-11-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Peptidomimetic macrocycle
WO2010034031A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2009294877C1 (en) * 2008-09-22 2015-05-07 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010034026A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010034034A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9458202B2 (en) 2008-11-24 2016-10-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2012515172A (en) * 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド Peptidomimetic macrocycle
EP2376100A4 (en) * 2009-01-14 2013-08-14 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
US10022422B2 (en) 2009-01-14 2018-07-17 Alleron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2012519180A (en) * 2009-02-27 2012-08-23 ミメトゲン ファーマシュウティカルズ インコーポレイテッド Peptidomimetic cyclic compounds for treating retinitis pigmentosa
AU2010217889B2 (en) * 2009-02-27 2014-12-18 Mimetogen Pharmaceuticals Inc. Peptidomimetic cyclic compounds for treating retinitis pigmentosa
US8653036B2 (en) 2009-02-27 2014-02-18 Mimetogen Pharmaceuticals Inc. Methods of treating retinitis pigmentosa
WO2010099436A1 (en) * 2009-02-27 2010-09-02 Mimetogen Pharmaceuticals, Inc. Methods of treating retinitis pigmentosa
US10300109B2 (en) 2009-09-22 2019-05-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9957299B2 (en) 2010-08-13 2018-05-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US11008366B2 (en) 2010-08-13 2021-05-18 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10703780B2 (en) 2010-08-13 2020-07-07 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9522947B2 (en) 2011-10-18 2016-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10308699B2 (en) 2011-10-18 2019-06-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN107216380A (en) * 2012-02-15 2017-09-29 爱勒让治疗公司 Peptidomimetic macrocyclic compound
US10967042B2 (en) 2012-02-15 2021-04-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10213477B2 (en) 2012-02-15 2019-02-26 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10227380B2 (en) 2012-02-15 2019-03-12 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104159595A (en) * 2012-02-15 2014-11-19 爱勒让治疗公司 Peptidomimetic macrocycles
WO2013126703A1 (en) * 2012-02-22 2013-08-29 New York University Reversibly crosslinked helical hydrogen bond surrogate macrocycles
US10669230B2 (en) 2012-11-01 2020-06-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9845287B2 (en) 2012-11-01 2017-12-19 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US11155577B2 (en) 2015-06-22 2021-10-26 University Of Utah Research Foundation Thiol-ene based peptide stapling and uses thereof
EP3310373A4 (en) * 2015-06-22 2019-02-13 University of Utah Research Foundation THIOL-EN-BASED PEPTIDE HOLDING AND USES THEREOF
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
US11034720B2 (en) 2016-07-17 2021-06-15 University Of Utah Research Foundation Thiol-yne based peptide stapling and uses thereof
WO2025040657A1 (en) * 2023-08-21 2025-02-27 Medizinische Universität Wien Selective cyclized peptide kappa-opioid receptor antagonists

Also Published As

Publication number Publication date
EP2094721A4 (en) 2011-01-19
CN101636407B (en) 2015-08-26
US10328117B2 (en) 2019-06-25
CA2686827A1 (en) 2008-06-26
EP2094721A1 (en) 2009-09-02
US20090047711A1 (en) 2009-02-19
CN101636407A (en) 2010-01-27
EP3170835A1 (en) 2017-05-24
US20170296620A1 (en) 2017-10-19
AU2007333846A1 (en) 2008-06-26
JP6259861B2 (en) 2018-01-10
EP2094721B1 (en) 2018-02-14
JP5656407B2 (en) 2015-01-21
JP2016199546A (en) 2016-12-01
WO2008076904A9 (en) 2017-04-27
IL199301A (en) 2014-09-30
JP2010513314A (en) 2010-04-30
HK1137184A1 (en) 2010-07-23
AU2007333846B2 (en) 2014-01-23
US20160095896A1 (en) 2016-04-07
US20100184628A1 (en) 2010-07-22
CN105061577A (en) 2015-11-18
BRPI0720306A2 (en) 2014-02-04
US20140135473A1 (en) 2014-05-15
US9175056B2 (en) 2015-11-03
US9675661B2 (en) 2017-06-13
US7960506B2 (en) 2011-06-14
CA2686827C (en) 2014-09-16
US8609809B2 (en) 2013-12-17
JP5931975B2 (en) 2016-06-08
JP2014231516A (en) 2014-12-11

Similar Documents

Publication Publication Date Title
US10328117B2 (en) Bis-sulfhydryl macrocyclization systems
EP2564863B1 (en) Triazole linked macrocyclic peptides
AU2016216698B2 (en) Peptidomimetic macrocycles with improved properties
EP2342222B1 (en) Peptidomimetic macrocycles
US7981998B2 (en) Bis-sulfhydryl macrocyclization systems
EP2310407A2 (en) Biologically active peptidomimetic macrocycles
AU2017201310A1 (en) Bis-sulfhydryl macrocyclization systems
HK1137184B (en) Bis-sulfhydryl macrocyclization systems

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780050407.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07869296

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009541617

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007333846

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007869296

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2686827

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3948/DELNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007333846

Country of ref document: AU

Date of ref document: 20071214

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0720306

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090615